<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Paliperidone: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Paliperidone: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Paliperidone: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10174" href="/d/html/10174.html" rel="external">see "Paliperidone: Drug information"</a> and <a class="drug drug_patient" data-topicid="10920" href="/d/html/10920.html" rel="external">see "Paliperidone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709193"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Increased mortality in elderly patients with dementia-related psychosis: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Paliperidone is not approved for the treatment of patients with dementia-related psychosis.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F3981432"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Invega;</li>
<li>Invega Hafyera;</li>
<li>Invega Sustenna;</li>
<li>Invega Trinza</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868844"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Invega;</li>
<li>Invega Sustenna;</li>
<li>Invega Trinza;</li>
<li>MAR-Paliperidone</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F15513469"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antipsychotic Agent, Benzisoxazole</span>;</li>
<li>
<span class="list-set-name">Second Generation (Atypical) Antipsychotic</span></li></ul></div>
<div class="block dop drugH1Div" id="F12761050"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="22a52188-c0f0-4e8c-9c4e-e8bbd9c46044">Irritability associated with autistic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Irritability associated with autistic disorder:</b> Limited data available: Children ≥12 years and Adolescents: Oral: Extended-release tablet: Initial: 3 mg once daily; titrate on a weekly basis in 3 mg/day increments until clinical response or intolerance; maximum daily dose: 12 mg/<b>day</b>. Dosing based on an open-label trial of 25 patients (mean age: 15.3 years; age range: 12 to 21 years); therapeutic response was reported in 84% of patients at a mean final dose: 7.1 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22549762']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22549762'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1c0197e0-ca33-4766-b087-4d1f00c456a2">Schizoaffective disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizoaffective disorder: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Adolescents ≥18 years: Oral: Extended-release tablet: Usual dose: 6 mg once daily (administered in the morning in clinical trials); titration not required, though some may benefit from lower or higher doses (range: 3 to 12 mg daily). If exceeding 6 mg daily, increases of 3 mg daily are recommended at intervals of more than 4 days, up to a maximum daily dose: 12 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Parenteral: Adolescents ≥18 years: IM: Due to complexity of product formulations, conversions of formulations, and schedule management, dosing for the monthly injection (Invega Sustenna) in adolescents ≥18 years of age is addressed in "Dosing: Adult."</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c642acd-fa55-4d9d-a66b-f25756b729c3">Schizophrenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents &lt;18 years: Oral: Extended-release tablet: 3 mg once daily; titration not necessary; if after clinical assessment a dosage increase is required, may increase dose in 3 mg/day increments at least every 5 days; maximum daily dose is weight dependent: &lt;51 kg: 6 mg/<b>day</b>; ≥51 kg: 12 mg/<b>day</b>; <b>Note:</b> During adolescent clinical trials, higher doses were not associated with greater efficacy, but increased risk of adverse effects.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥18 years: Oral: Extended-release tablet: Usual dose: 6 mg once daily (administered in the morning in clinical trials); titration not required, though some may benefit from lower or higher doses (range: 3 to 12 mg daily). If exceeding 6 mg daily, increases of 3 mg daily are recommended no more frequently than every 5 days, up to a maximum of 12 mg daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Parenteral: Adolescents ≥18 years: <b></b>IM: Due to complexity of product formulations and variations in recommendations, dosing for the monthly injection (Invega Sustenna), 3-month injection (Invega Trinza), and 6-month injection (Invega Hafyera) in adolescents ≥18 years of age is addressed in "Dosing: Adult."</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for toxicity:</b> Children ≥12 years and Adolescents: Severe neutropenia (ANC &lt;1,000/mm<sup>3</sup>): Discontinue treatment.</p></div>
<div class="block dorp drugH1Div" id="F51151402"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents ≤17 years: There are no dosage adjustments provided in the manufacturer's labeling for pediatric patients ≤17 years; clearance is decreased in renal impairment; adjust dose according to renal function. In adolescents ≥18 years and adults, doses reductions are suggested.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥80 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 50 to 79 mL/minute: Initial dose: 3 mg once daily; maximum dose: 6 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to 49 mL/minute: Initial dose: 1.5 mg once daily; maximum dose: 3 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute: Use not recommended (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Adolescents ≥18 years: Due to complexity of product formulations and variations in recommendations, dosing for the monthly injection (Invega Sustenna), 3-month injection (Invega Trinza), and 6-month injection (Invega Hafyera) in adolescents ≥18 years of age is addressed in "Dosing: Altered Kidney Function: Adult."</p></div>
<div class="block dohp drugH1Div" id="F51151403"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥12 years and Adolescents: Oral, IM:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F3982410"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10174" href="/d/html/10174.html" rel="external">see "Paliperidone: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Paliperidone is a major, active metabolite of risperidone.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="73231ee1-15e9-46b2-833c-24d7994c2cd5">Schizophrenia and schizoaffective disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia and schizoaffective disorder:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 6 mg once daily; may adjust daily dose based on response and tolerability in increments of 3 mg every ≥5 days up to a maximum of 12 mg/day. Usual dosage range: 6 to 12 mg/day. <b>Note:</b> According to manufacturer's labeling, 3 mg/day may be effective for some patients (eg, those who do not tolerate 6 mg/day).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Formulation contains paliperidone palmitate. Dosing in the US labeling is based on paliperidone palmitate; dosing in the Canadian labeling is based on paliperidone base (paliperidone palmitate 1 mg is equivalent to paliperidone base ~0.64 mg). <b></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Monthly paliperidone (Invega Sustenna):</b>
<b>Note:</b> Before starting monthly IM paliperidone, establish tolerability with a test dose of oral paliperidone or oral risperidone. After initiating monthly IM paliperidone, overlap with oral antipsychotics is not necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lauriello.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lauriello.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i></i></b>
<b>
<i>Initiation: </i></b> 234 mg (150 mg as base) on treatment day 1 followed by 156 mg (100 mg as base) 1 week later, with both doses administered in the deltoid muscle. The second dose may be administered 4 days before or after the 1-week time point. <b>Note: </b>When converting from other long-acting injectable antipsychotics (at steady state), initiation doses are not required.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Managing Missed Paliperidone Dose: Second Initiation Dose</b></caption>
<colgroup><col align="center"/>
<col/>
</colgroup><thead valign="bottom">
<tr>
<th align="center">
<p style="text-indent:0em;">Time since first injection</p></th>
<th align="left">
<p style="text-indent:0em;text-align:center;">Instructions</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;4 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">Administer 156 mg (100 mg as base) in the deltoid muscle as soon as possible, followed by 117 mg (75 mg as base) in either the deltoid or gluteal muscle 5 weeks after the first injection (regardless of when 156 mg dose was administered). Then begin monthly maintenance dose 4 weeks later.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">4 to 7 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">Administer 156 mg (100 mg as base) in the deltoid muscle as soon as possible, followed by another 156 mg (100 mg as base) dose in the deltoid muscle 1 week later. Then begin monthly maintenance dose 4 weeks later.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;7 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">Reinitiate entire dose titration.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Maintenance:</i></b> Five weeks after the first initiation dose, begin a maintenance dose of 39 to 234 mg (25 to 150 mg as base) every month administered in either the deltoid or gluteal muscle. Maximum: 234 mg (150 mg as base)/month. See the “Dose Conversions That Attain Similar Steady-State Paliperidone Exposure During Maintenance Treatment” table to identify an appropriate maintenance dose based on previous oral paliperidone dose or risperidone dose. The monthly maintenance dose may be administered 7 days before or after the monthly time point.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Managing Missed Paliperidone Dose: Monthly IM Maintenance Dose</b></caption>
<colgroup><col align="center"/>
<col/>
</colgroup><thead valign="bottom">
<tr>
<th align="center">
<p style="text-indent:0em;">Time since last injection</p></th>
<th align="left">
<p style="text-indent:0em;text-align:center;">Instructions</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">4 to 6 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">Administer the missed dose as soon as possible. Then resume usual monthly maintenance dose 4 weeks later.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;6 weeks to 6 months</p></td>
<td align="left">
<p style="text-indent:0em;">
<i>Maintenance dose 39 to 156 mg (25 to 100 mg as base):</i> Administer 2 maintenance doses in the deltoid muscle 1 week apart. Then resume usual monthly maintenance dose 4 weeks later.</p>
<p style="text-indent:0em;">
<i>Maintenance dose 234 mg (150 mg as base):</i> Administer 156 mg (100 mg as base) in the deltoid muscle as soon as possible, followed by another 156 mg (100 mg as base) in the deltoid muscle 1 week later. Then resume usual monthly maintenance dose 4 weeks later.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;6 months</p></td>
<td align="left">
<p style="text-indent:0em;">Reinitiate entire dose titration.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Dosage adjustments: </i></b>Adjustments may be made monthly based on response and tolerability; the full effect from dose adjustments may not be apparent for several months.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>3-month paliperidone (FDA-approved for schizophrenia only) (Invega Trinza):</b>
<b>Note:</b> 3-month IM paliperidone is to be used only after 4 doses of monthly IM paliperidone (Invega Sustenna). The last 2 doses of monthly IM paliperidone should be the same dosage strength before starting 3-month IM paliperidone.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Conversion from monthly IM paliperidone to 3-month IM paliperidone</i></b>
<i>:</i> Initiate 3-month IM paliperidone when the next monthly IM paliperidone dose is scheduled. Base the 3-month dose on the previous monthly dose, using the “Dose Conversions That Attain Similar Steady-State Paliperidone Exposure During Maintenance Treatment” table. 3-month IM paliperidone may be administered up to 7 days before or after the next monthly dose is due. Following the initial injection, administer every 3 months. Maintenance injections may be administered up to 2 weeks before or after the 3-month time point.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Managing Missed Paliperidone Dose: 3-month IM Maintenance Dose</b></caption>
<colgroup><col/>
<col/>
</colgroup><thead valign="bottom">
<tr>
<th align="left">
<p style="text-indent:0em;text-align:center;">Time since last injection</p></th>
<th align="left">
<p style="text-indent:0em;text-align:center;">Instructions</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;">3.5 to &lt;4 months</p></td>
<td align="left">
<p style="text-indent:0em;">Administer the missed dose as soon as possible. Then resume usual maintenance dose 3 months later.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4 to 9 months</p></td>
<td align="left">
<p style="text-indent:0em;">
<i>Maintenance dose 273 mg (175 mg as base):</i> Administer 78 mg (50 mg as base) of <b>monthly IM paliperidone </b>(Invega Sustenna) into the deltoid muscle on days 1 and 8. One month following the second injection, administer 273 mg (175 mg as base) of <b>3-month IM paliperidone </b>(Invega Trinza) into the deltoid or gluteal muscle and resume usual dosing at 3-month intervals.</p>
<p style="text-indent:0em;">
<i>Maintenance dose 410 mg (263 mg as base):</i> Administer 117 mg (75 mg as base) of <b>monthly IM paliperidone </b>(Invega Sustenna) into the deltoid muscle on days 1 and 8. One month following the second injection, administer 410 mg (263 mg as base) of <b>3-month IM paliperidone </b>(Invega Trinza) into the deltoid or gluteal muscle and resume usual dosing at 3-month intervals.</p>
<p style="text-indent:0em;">
<i>Maintenance dose 546 mg (350 mg as base):</i> Administer 156 mg (100 mg as base) of <b>monthly IM paliperidone </b>(Invega Sustenna) into the deltoid muscle on days 1 and 8. One month following the second injection, administer 546 mg (350 mg as base) of <b>3-month IM paliperidone </b>(Invega Trinza) into the deltoid or gluteal muscle and resume usual dosing at 3-month intervals.</p>
<p style="text-indent:0em;">
<i>Maintenance dose 819 mg (525 mg as base):</i> Administer 156 mg (100 mg as base) of <b>monthly IM</b>
<b>paliperidone </b>(Invega Sustenna) into the deltoid muscle on days 1 and 8. One month following the second injection, administer 819 mg (525 mg as base) of <b>3-month IM paliperidone </b>(Invega Trinza) into the deltoid or gluteal muscle and resume usual dosing at 3-month intervals.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;9 months</p></td>
<td align="left">
<p style="text-indent:0em;">Reinitiate treatment with <b>monthly IM paliperidone</b> (Invega Sustenna). <b>3-month IM paliperidone</b> (Invega Trinza) can be resumed after the patient has been adequately treated with monthly IM paliperidone for at least 4 months.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Dosage adjustments: </i></b>Incremental dose adjustment can be made every 3 months based on response and tolerability to achieve usual dose of 273 to 819 mg (175 to 525 mg as base); response to an adjusted dose may not be apparent for several months.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>6-month paliperidone (FDA-approved for schizophrenia only) (Invega Hafyera):</b>
<b>Note:</b> 6-month IM paliperidone is to be used only after either 4 doses of monthly IM paliperidone (Invega Sustenna) <b>or</b> 1 dose of 3-month IM paliperidone (Invega Trinza). The dose immediately preceding the 6-month IM injection can either be a monthly IM injection or a 3-month IM injection.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>
<b>Conversion from monthly IM paliperidone to 6-month IM paliperidone</b>:</i> Administer the same dose for the 2 monthly injection cycles immediately preceding the first 6-month IM injection. Initiate 6-month IM paliperidone when the next monthly IM paliperidone dose is scheduled. Base the 6-month dose on the previous monthly dose, using the “Dose Conversions That Attain Similar Steady-State Paliperidone Exposure During Maintenance Treatment” table. 6-month IM paliperidone may be administered up to 1 week before or after the next monthly dose is due. Following the initial injection, administer every 6 months. Maintenance injections may be administered up to 2 weeks before or 3 weeks after the 6-month time point.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>
<b>Conversion from 3-month IM paliperidone to 6-month IM paliperidone</b>:</i> Initiate 6-month IM paliperidone when the next 3-month IM paliperidone dose is scheduled. Base the 6-month dose on the previous 3-month dose, using the “Dose Conversions That Attain Similar Steady-State Paliperidone Exposure During Maintenance Treatment” table. 6-month IM paliperidone may be administered up to 2 weeks before or after the next 3-month dose is due. Following the initial injection, administer every 6 months. Maintenance injections may be administered up to 2 weeks before or 3 weeks after the 6-month time point.</p>
<table border="1" frame="border" rules="all">
<caption>
<b>Managing Missed Paliperidone Dose: 6-month IM Maintenance Dose</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Time since last injection</p></th>
<th align="center">
<p style="text-indent:0em;">Instructions</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">6 months and 3 weeks to &lt;8 months</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance dose 1,092 mg: </i>Do not administer the missed dose. Administer 156 mg (100 mg as base) of <b>monthly IM paliperidone </b>(Invega Sustenna) into the deltoid muscle on day 1. One month after the day 1 injection, administer 1,092 mg of <b>6-month IM paliperidone </b>(Invega Hafyera) into the gluteal muscle and resume usual dosing at 6-month intervals.</p>
<p style="text-indent:0em;">
<i>Maintenance dose 1,560 mg: </i>Do not administer the missed dose. Administer 234 mg (150 mg as base) of <b>monthly IM paliperidone </b>(Invega Sustenna) into the deltoid muscle on day 1. One month after the day 1 injection, administer 1,560 mg of <b>6-month IM paliperidone </b>(Invega Hafyera) into the gluteal muscle and resume usual dosing at 6-month intervals.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8 to 11 months</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance dose 1,092 mg: </i>Do not administer the missed dose. Administer 156 mg (100 mg as base) of <b>monthly IM paliperidone </b>(Invega Sustenna) into the deltoid muscle on days 1 and 8. One month after the day 8 injection, administer 1,092 mg of <b>6-month IM paliperidone </b>(Invega Hafyera) into the gluteal muscle and resume usual dosing at 6-month intervals.</p>
<p style="text-indent:0em;">
<i>Maintenance dose 1,560 mg: </i>Do not administer the missed dose. Administer 156 mg (100 mg as base) of <b>monthly IM paliperidone </b>(Invega Sustenna) into the deltoid muscle on days 1 and 8. One month after the day 8 injection, administer 1,560 mg of <b>6-month IM paliperidone </b>(Invega Hafyera) into the gluteal muscle and resume usual dosing at 6-month intervals.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;11 months</p></td>
<td align="center">
<p style="text-indent:0em;">Reinitiate treatment with <b>monthly IM paliperidone</b> (Invega Sustenna). <b>6-month IM paliperidone</b> (Invega Hafyera) can be resumed after the patient has been adequately treated with monthly IM paliperidone for at least 4 months.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">
<i>
<b>Dosage adjustments: </b></i>Incremental dose adjustment can be made every 6 months based on response and tolerability to achieve usual dose of 1,092 to 1,560 mg; response to an adjusted dose may not be apparent for several months.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Dose Conversions That Attain Similar Steady-State Paliperidone Exposure During Maintenance Treatment</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="bottom">
<tr>
<th align="center">
<p style="text-indent:0em;">Paliperidone ER tablet</p></th>
<th align="center">
<p style="text-indent:0em;">Paliperidone palmitate monthly IM injection <b>(Invega Sustenna)</b></p></th>
<th align="center">
<p style="text-indent:0em;">Paliperidone palmitate 3-month IM injection (Invega Trinza)</p></th>
<th align="center">
<p style="text-indent:0em;">Paliperidone palmitate 6-month IM injection (Invega Hafyera)</p></th>
<th align="center">
<p style="text-indent:0em;">Risperidone ER IM injection (Risperdal Consta)</p></th>
<th align="center">
<p style="text-indent:0em;">Risperidone tablet</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="6">
<p style="text-indent:0em;text-align:left;">
<b>Converting from 3-month IM paliperidone to paliperidone ER tablets:</b> Do not use above table to determine appropriate dose, which is based on injection dose and weeks since last administration. Refer to the “Conversion From 3-Month IM Paliperidone to Paliperidone ER Tablets” table to determine oral dose.</p>
<p style="text-indent:0em;text-align:left;">
<b>Converting from 3-month IM paliperidone to monthly IM paliperidone: </b>Initiate monthly IM paliperidone when the next 3-month IM paliperidone dose is scheduled. Base the monthly dose on the previous 3-month dose. Following the initial injection, administer once monthly.</p>
<p style="text-indent:0em;text-align:left;">
<b>Converting from other oral antipsychotics to long-acting injectable paliperidone:</b> There are no systematically collected data to address switching patients from other oral antipsychotics to IM paliperidone.</p>
<p style="text-indent:0em;text-align:left;">
<b>Converting from other long-acting injectable antipsychotics (at steady state) to monthly IM paliperidone:</b> Initiate monthly IM paliperidone in the place of the next scheduled injection and continue at monthly intervals. The 2 initiation doses are not required in these patients.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">3 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">39 mg (25 mg as base) every month</p></td>
<td align="center">
<p style="text-indent:0em;">Has not been studied</p></td>
<td align="center">
<p style="text-indent:0em;">Has not been studied</p></td>
<td align="center">
<p style="text-indent:0em;">No information available</p></td>
<td align="center">
<p style="text-indent:0em;">1 mg/day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">78 mg (50 mg as base) every month</p></td>
<td align="center">
<p style="text-indent:0em;">273 mg (175 mg as base) every 3 months</p></td>
<td align="center">
<p style="text-indent:0em;">Has not been studied</p></td>
<td align="center">
<p style="text-indent:0em;">25 mg every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">2 mg/day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">6 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">117 mg (75 mg as base) every month</p></td>
<td align="center">
<p style="text-indent:0em;">410 mg (263 mg as base) every 3 months</p></td>
<td align="center">
<p style="text-indent:0em;">Has not been studied</p></td>
<td align="center">
<p style="text-indent:0em;">37.5 mg every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">3 mg/day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">9 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">156 mg (100 mg as base) every month</p></td>
<td align="center">
<p style="text-indent:0em;">546 mg (350 mg as base) every 3 months</p></td>
<td align="center">
<p style="text-indent:0em;">1,092 mg every 6 months</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg every 2 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">4 mg/day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">12 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">234 mg (150 mg as base) every month</p></td>
<td align="center">
<p style="text-indent:0em;">819 mg (525 mg as base) every 3 months</p></td>
<td align="center">
<p style="text-indent:0em;">1,560 mg every 6 months</p></td>
<td align="center">
<p style="text-indent:0em;">No information available</p></td>
<td align="center">
<p style="text-indent:0em;">5 mg/day</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Conversion from 3-month IM paliperidone to paliperidone ER tablets:</i></b> Initiate paliperidone ER tablets ≥3 months after the last dose of 3-month IM paliperidone. Base the once-daily ER tablet dose on the last 3-month injection dose and weeks since last administered, using the following table:</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Converting From 3-month IM Paliperidone to Paliperidone ER Tablets</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" rowspan="2"></th>
<th align="center" colspan="3">
<p style="text-indent:0em;">
<b>Weeks since last 3-month IM injection </b></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>≥12 weeks to 18 weeks </b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>&gt;18 weeks to 24 weeks</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b> &gt;24 weeks </b></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Last 3-month IM injection dose </b></p></th>
<th align="center" colspan="3">
<p style="text-indent:0em;">
<b>Daily dose of oral paliperidone ER tablet</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">273 mg (175 mg as base)</p></td>
<td align="center">
<p style="text-indent:0em;">3 mg</p></td>
<td align="center">
<p style="text-indent:0em;">3 mg</p></td>
<td align="center">
<p style="text-indent:0em;">3 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">410 mg (263 mg as base)</p></td>
<td align="center">
<p style="text-indent:0em;">3 mg</p></td>
<td align="center">
<p style="text-indent:0em;">3 mg</p></td>
<td align="center">
<p style="text-indent:0em;">6 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">546 mg (350 mg as base)</p></td>
<td align="center">
<p style="text-indent:0em;">3 mg</p></td>
<td align="center">
<p style="text-indent:0em;">6 mg</p></td>
<td align="center">
<p style="text-indent:0em;">9 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">819 mg (525 mg as base)</p></td>
<td align="center">
<p style="text-indent:0em;">6 mg</p></td>
<td align="center">
<p style="text-indent:0em;">9 mg</p></td>
<td align="center">
<p style="text-indent:0em;">12 mg</p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oral</i>
<i>:</i> In the treatment of chronic psychiatric disease switching therapy rather than discontinuation is generally advised if side effects are intolerable or treatment is not effective. If patient insists on stopping treatment, gradual dose reduction (ie, over several weeks to months) is advised to detect a re-emergence of symptoms and to avoid withdrawal reactions (eg, agitation, alternating feelings of warmth and chill, anxiety, diaphoresis, dyskinesias, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, vertigo) unless discontinuation is due to significant adverse effects. Monitor closely to allow for detection of prodromal symptoms of disease recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516','lexi-content-ref-17650054','lexi-content-ref-32670542','lexi-content-ref-Post.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516','lexi-content-ref-17650054','lexi-content-ref-32670542','lexi-content-ref-Post.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Long-</i>
<i>acting injectable</i>: Switching to other treatments is generally advised if side effects are intolerable or treatment is not effective. However, if a patient insists on stopping treatment, gradual dose reduction to avoid withdrawal reactions is generally <b>not</b> needed with long-acting injectable antipsychotics. The risk of withdrawal symptoms from discontinuation of long-acting injectables is low because the rate of drug elimination is slow. Monitor closely to allow for detection of prodromal symptoms of disease recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516','lexi-content-ref-23343447','lexi-content-ref-Steinman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516','lexi-content-ref-23343447','lexi-content-ref-Steinman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Switching </b>
<b>antipsychotics:</b> An optimal universal strategy for switching antipsychotic drugs has not been established. Strategies include: Cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic) and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). In patients with schizophrenia at high risk of relapse, the current medication may be maintained at full dose as the new medication is increased (ie, overlap); once the new medication is at therapeutic dose, the first medication is gradually decreased and discontinued over 1 to 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039','lexi-content-ref-15949658','lexi-content-ref-28044008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039','lexi-content-ref-15949658','lexi-content-ref-28044008'])">Ref</a></span>). Based upon clinical experience, some experts generally prefer cross-titration and overlap approaches rather than abrupt change (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stroup.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stroup.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990341"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Paliperidone Dose Adjustments for Altered Kidney Function</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl</p></th>
<th align="center">
<p style="text-indent:0em;">Oral ER tablet</p></th>
<th align="center">
<p style="text-indent:0em;">Monthly IM injection (Invega Sustenna)</p></th>
<th align="center">
<p style="text-indent:0em;">3-month IM injection (Invega Trinza)</p></th>
<th align="center">
<p style="text-indent:0em;">6-month IM injection (Invega Hafyera)</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Since there are limited data on the use of long-acting injectable formulations in patients with kidney impairment, use of oral paliperidone or other alternative therapeutic options has been suggested (Schoretsanitis 2018).</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">CrCl ≥90 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">80 to &lt;90 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary.</p></td>
<td align="center">
<p style="text-indent:0em;">Use not recommended.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">50 to &lt;80 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">Initial: 3 mg once daily; maximum: 6 mg once daily.</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>
<b>Initiation:</b></i> 156 mg (as palmitate) or 100 mg (as base) on treatment day 1, followed by 117 mg (as palmitate) or 75 mg (as base) 1 week later with both doses administered in the deltoid.</p>
<p style="text-indent:0em;">
<i>
<b>Maintenance:</b></i> Five weeks after the first initiation dose, begin a maintenance dose of 78 mg (as palmitate) or 50 mg (as base) every month administered in either the deltoid or gluteal muscle. The dose can be subsequently adjusted to 39 to 156 mg (25 to 100 mg as base) every month administered in either the deltoid or gluteal muscle.<sup>a </sup> Maximum: 156 mg (100 mg as base)/month.</p></td>
<td align="center">
<p style="text-indent:0em;">Adjust dosage and stabilize the patient using the monthly IM injection, then transition to the 3-month IM injection.<sup>a</sup></p>
<p style="text-indent:0em;">
<b>Note:</b> Monthly IM paliperidone (Invega Sustenna) 78 mg (as palmitate) or 50 mg (as base) = 3-month IM paliperidone (Invega Trinza) 273 mg (as palmitate) or 175 mg (as base).</p></td>
<td align="center">
<p style="text-indent:0em;">Use not recommended.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">10 to &lt;50 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">Initial: 1.5 mg once daily; maximum: 3 mg once daily.</p></td>
<td align="center" colspan="3">
<p style="text-indent:0em;">Use not recommended.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;10 mL/minute</p></td>
<td align="center" colspan="4">
<p style="text-indent:0em;">Use not recommended.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25914108']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25914108'])">Ref</a></span>): Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not likely to be significantly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>): Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987703"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral, IM (monthly, 3-month <b></b>or 6-month):</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F56882405"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Angioedema</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Potentially life-threatening<b> angioedema</b> has been reported very rarely following oral and IM paliperidone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29028688','lexi-content-ref-33195656','lexi-content-ref-26125544']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29028688','lexi-content-ref-33195656','lexi-content-ref-26125544'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; immunologic and non-immunologic mechanisms have been proposed, including IgE-related hypersensitivity, kinin-dependent processes, or C<sub>1</sub>-esterase inhibition deficiencies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31534873']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31534873'])">Ref</a></span>). An excipient (eg, polysorbate, polyethylene glycol) contained in the paliperidone IM formulation may also be a possible allergen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33737254','lexi-content-ref-29028688','lexi-content-ref-22180550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33737254','lexi-content-ref-29028688','lexi-content-ref-22180550'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; Oral: Onset occurred during the second week of oral therapy, but a few hours following dosage increase from the initial dose of 3 mg/day to 6 mg/day. IM: 17 to 60 days following IM administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29028688','lexi-content-ref-33195656','lexi-content-ref-26125544']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29028688','lexi-content-ref-33195656','lexi-content-ref-26125544'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose-dependency: Increased risk of angioedema with increased dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33195656','lexi-content-ref-26125544']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33195656','lexi-content-ref-26125544'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Route of administration: Tolerance to oral paliperidone but development of angioedema with IM paliperidone has been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29028688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29028688'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dyslipidemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics are associated with dyslipidemia in adult and pediatric patients, which is a component of the metabolic syndrome observed with this pharmacologic class. Although data are inconsistent regarding paliperidone’s risk, the following events have been observed: <b>Increased serum cholesterol</b>, <b>decreased HDL cholesterol</b>, and/or<b> increased serum triglycerides </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28140680','lexi-content-ref-24241935','lexi-content-ref-33686614','lexi-content-ref-22722501','lexi-content-ref-32648200','lexi-content-ref-32715655','lexi-content-ref-24446539']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28140680','lexi-content-ref-24241935','lexi-content-ref-33686614','lexi-content-ref-22722501','lexi-content-ref-32648200','lexi-content-ref-32715655','lexi-content-ref-24446539'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> The mechanism is not entirely understood and is likely multifactorial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26218604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26218604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; metabolic alterations from antipsychotics can develop in as short as 3 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14747245','lexi-content-ref-26218604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14747245','lexi-content-ref-26218604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents may be at increased risk for increased serum triglycerides with second-generation antipsychotic use (data does not involve use of paliperidone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19861668']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19861668'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• A higher BMI (potential risk factor) is potentially associated with higher risk of metabolic-related adverse events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24559194']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24559194'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Schizophrenia (regardless of medication use) is associated with a higher rate of morbidity/mortality compared to the general population primarily due to cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15151456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15151456'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Paliperidone is usually considered to have a low risk for causing lipid abnormalities in adults, although data are inconsistent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159','lexi-content-ref-28140680']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159','lexi-content-ref-28140680'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Extrapyramidal symptoms</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Paliperidone is frequently associated with extrapyramidal symptoms (EPS), also known as drug-induced movement disorders in adult and pediatric patients. Antipsychotics can cause 4 main EPS: Acute<b> dystonia</b>, drug-induced <b>parkinsonism</b>, <b>akathisia</b>, and <b>dyskinesia </b>(which includes<b> tardive dyskinesia</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24092977','lexi-content-ref-25358867','lexi-content-ref-20706126','lexi-content-ref-28140680','lexi-content-ref-26218669','lexi-content-ref-32648200','lexi-content-ref-28721057','lexi-content-ref-30192094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24092977','lexi-content-ref-25358867','lexi-content-ref-20706126','lexi-content-ref-28140680','lexi-content-ref-26218669','lexi-content-ref-32648200','lexi-content-ref-28721057','lexi-content-ref-30192094'])">Ref</a></span>). EPS presenting as <b>dysphagia</b>, esophageal dysmotility, or aspiration have also been reported with antipsychotics, which may not be recognized as EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> EPS: Dose-related; due to antagonism of dopaminergic D<sub>2</sub> receptors in nigrostriatal pathways (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12927004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12927004'])">Ref</a></span>). Tardive dyskinesia: Time-related (delayed); results from chronic exposure to dopamine 2 receptor antagonists leading to up-regulation of these receptors over time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23858394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23858394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Acute dystonia:</span> Rapid; in the majority of cases, dystonia usually occurs within the first 5 days after initiating antipsychotic therapy (and even with the first dose, particularly in patients receiving parenteral antipsychotics) or a dosage increase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Drug-induced parkinsonism:</span> Varied; onset may be delayed from days to weeks, with 50% to 75% of cases occurring within 1 month and 90% within 3 months of antipsychotic initiation, a dosage increase, or a change in the medication regimen (such as adding another antipsychotic agent or discontinuing an anticholinergic medication) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Akathisia:</span> Varied; may begin within several days after antipsychotic initiation but usually increases with treatment duration, occurring within 1 month in up to 50% of cases and within 3 months in 90% of cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Tardive dyskinesia:</span> Delayed; symptoms usually appear after 1 to 2 years of continuous exposure to a dopamine 2 receptor antagonist and almost never before 3 months with an insidious onset, evolving into a full syndrome over days and weeks, followed by symptom stabilization and then a chronic waxing and waning of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23858394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23858394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Esophageal dysfunction (associated with EPS)</span>: Varied; ranges from weeks to months following initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14565800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14565800'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">EPS (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Prior history of EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Younger age (in general, children and adolescents are usually at higher risk for EPS compared to adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18533766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18533766'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific antipsychotic: Paliperidone, the primary active metabolite of risperidone, is usually associated with a moderate to high propensity to cause EPS, similar to risperidone’s propensity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187598','lexi-content-ref-28721057','lexi-content-ref-30192094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187598','lexi-content-ref-28721057','lexi-content-ref-30192094'])">Ref</a></span>). Some limited data suggests that switching from risperidone to paliperidone improved preexisting EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24047427']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24047427'])">Ref</a></span>). The once monthly paliperidone formulation has been associated with a lower incidence of EPS compared with oral paliperidone, and the 3-month paliperidone formulation has been found to have a similar incidence of EPS compared to the once monthly paliperidone in patients with schizophrenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30498351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30498351'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Acute dystonia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Young age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced parkinsonism:</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Akathisia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher antipsychotic dosages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Polypharmacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Mood disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Tardive dyskinesia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;55 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Cognitive impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant treatment with anticholinergic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diagnosis of schizophrenia or affective disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31325958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31325958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390261'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Greater total antipsychotic exposure (especially first-generation antipsychotics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390261'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of extrapyramidal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Substance misuse or dependence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Race (White or African descent). <b>Note:</b> Although early literature supported race as a potential risk factor for tardive dyskinesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8102845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8102845'])">Ref</a></span>), newer studies have challenged this assertion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28146614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28146614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Esophageal dysfunction (associated with EPS):</p>
<p style="text-indent:-2em;margin-left:8em;">• Certain comorbidities such as neurologic degenerative disease, dementia, stroke, Parkinson disease, or myasthenia gravis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults &gt;75 years of age (may be risk factor due to age-related muscle atrophy, cognitive impairment, reduced esophageal peristalsis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic abnormalities</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leukopenia </b>and <b>neutropenia</b> have been reported rarely with paliperidone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20920543','lexi-content-ref-33549083','lexi-content-ref-22984110']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20920543','lexi-content-ref-33549083','lexi-content-ref-22984110'])">Ref</a></span>). <b>Agranulocytosis </b>has also been reported very rarely in a patient receiving a combination of paliperidone and risperidone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30636434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30636434'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Unclear and poorly understood (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28794632','lexi-content-ref-28558630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28794632','lexi-content-ref-28558630'])">Ref</a></span>). In cases where paliperidone is combined with risperidone, dose-related toxicity has been suspected as paliperidone is a major active metabolite of risperidone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20920543','lexi-content-ref-22984110','lexi-content-ref-30636434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20920543','lexi-content-ref-22984110','lexi-content-ref-30636434'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; in general, drug-induced neutropenia usually manifests after 1 or 2 weeks of exposure and agranulocytosis usually appears 3 to 4 weeks following initiation of therapy; however, the onset may be insidious (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18098216','lexi-content-ref-3819263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18098216','lexi-content-ref-3819263'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18098216','lexi-content-ref-3819263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18098216','lexi-content-ref-3819263'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of drug-induced leukopenia/neutropenia or low white blood cell count/absolute neutrophil count (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22984110']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22984110'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics are associated with <b>hyperglycemia </b>in adult and pediatric patients, to varying degrees, which is a component of the metabolic syndrome observed with this pharmacologic class. Although data are insufficient regarding paliperidone’s risk, the following events have been observed: Increased serum glucose (fasting), mild insulin resistance and<b> hyperinsulinemia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159','lexi-content-ref-22900950','lexi-content-ref-29097257','lexi-content-ref-27478670','lexi-content-ref-33686614','lexi-content-ref-24559194','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159','lexi-content-ref-22900950','lexi-content-ref-29097257','lexi-content-ref-27478670','lexi-content-ref-33686614','lexi-content-ref-24559194','lexi-content-ref-28721057'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> The mechanism is not entirely understood and is likely multifactorial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23278567']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23278567'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; new-onset diabetes has been observed within the first 3 months to a median onset of 3.9 years of atypical antipsychotic initiation (studies did not include paliperidone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20520598','lexi-content-ref-18348593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20520598','lexi-content-ref-18348593'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors (in general):</i></p>
<p style="text-indent:-2em;margin-left:6em;">• African American race (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12046641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12046641'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting obesity, poor exercise habits, or other risk factors for diabetes, including family history of diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Exposure to other agents that also increase the risk of hyperglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Risk of hyperglycemia and/or new onset diabetes appears to be low to moderate with paliperidone, although data are insufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159','lexi-content-ref-29097257','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159','lexi-content-ref-29097257','lexi-content-ref-28721057'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperprolactinemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Paliperidone commonly causes hyperprolactinemia/<b>increased serum prolactin</b> in adult and pediatric patients, which may lead to <b>gynecomastia, galactorrhea not associated with childbirth</b>, <b>amenorrhea</b>, <b>sexual disorder</b>, and infertility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19825908','lexi-content-ref-19113797','lexi-content-ref-22947594','lexi-content-ref-28660406','lexi-content-ref-34481200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19825908','lexi-content-ref-19113797','lexi-content-ref-22947594','lexi-content-ref-28660406','lexi-content-ref-34481200'])">Ref</a></span>). Although long-term effects of elevated prolactin levels have not been fully evaluated, some studies have also suggested a possible association between hyperprolactinemia and an increased risk for breast and/or pituitary tumors and osteopenia/osteoporosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19113797','lexi-content-ref-20331935','lexi-content-ref-16633146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19113797','lexi-content-ref-20331935','lexi-content-ref-16633146'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related and possibly time-related; antagonism of dopamine D<sub>2</sub> receptors in the tuberoinfundibular dopaminergic pathway which causes disinhibition of prolactin release resulting in hyperprolactinemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19958039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19958039'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; onset is typically within a few weeks following initiation or dosage increase, but may also arise after long-term stable use following atypical antipsychotic use (paliperidone not specifically studied) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187598'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Similar to risperidone, risperidone’s active metabolite, paliperidone (9-hydroxy-risperidone) is considered a prolactin-elevating antipsychotic with a high risk for hyperprolactinemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19825908','lexi-content-ref-31303314','lexi-content-ref-15863810','lexi-content-ref-23810019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19825908','lexi-content-ref-31303314','lexi-content-ref-15863810','lexi-content-ref-23810019'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19113797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19113797'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (particularly those of reproductive age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19958039','lexi-content-ref-19113797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19958039','lexi-content-ref-19113797'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19113797','lexi-content-ref-19364288']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19113797','lexi-content-ref-19364288'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Mortality in older adults</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Older adults with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17548409','lexi-content-ref-24416588','lexi-content-ref-25786075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17548409','lexi-content-ref-24416588','lexi-content-ref-25786075'])">Ref</a></span>). In addition, an increased incidence of cerebrovascular effects (eg, <b>cerebrovascular accident</b>, transient ischemic attacks), including fatalities, have been reported in placebo-controlled risperidone trials in older adults with dementia-related psychosis in elderly patients with dementia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24158020','lexi-content-ref-27133416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24158020','lexi-content-ref-27133416'])">Ref</a></span>). No studies have been conducted with paliperidone, a metabolite of risperidone. Of note, paliperidone is not approved for the treatment of dementia-related psychosis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Unknown; possible mechanisms include arrhythmia, cardiac arrest, and extrapyramidal effects that may increase the risk of falls, aspirations, and pneumonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24016844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24016844'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher antipsychotic dosage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25140533','lexi-content-ref-22193526','lexi-content-ref-25786075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25140533','lexi-content-ref-22193526','lexi-content-ref-25786075'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dementia-related psychosis (eg, Lewy body dementia, Parkinson disease dementia)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuroleptic malignant syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">All antipsychotics have been associated with <b>neuroleptic malignant syndrome</b> (NMS), although the incidence is less with second-generation (atypical) antipsychotics compared to first-generation (typical) antipsychotics. There are case reports of NMS with paliperidone, with several associated with the use of paliperidone palmitate long-acting IM injection, although there is also a single case report in a patient switching between oral risperidone and oral paliperidone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25578944','lexi-content-ref-30811377','lexi-content-ref-27721999','lexi-content-ref-21304113','lexi-content-ref-33605644','lexi-content-ref-18628446','lexi-content-ref-22231327','lexi-content-ref-22626633','lexi-content-ref-33520321']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25578944','lexi-content-ref-30811377','lexi-content-ref-27721999','lexi-content-ref-21304113','lexi-content-ref-33605644','lexi-content-ref-18628446','lexi-content-ref-22231327','lexi-content-ref-22626633','lexi-content-ref-33520321'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non–dose-related; idiosyncratic. Believed to be due to a reduction in CNS dopaminergic tone, along with the dysregulation of autonomic nervous system activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25578944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25578944'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; in general, most patients develop NMS within 2 weeks of initiating an antipsychotic, and in some patients, prodromal symptoms emerge within hours of initiation; once the syndrome starts, the full syndrome usually develops in 3 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17414689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17414689'])">Ref</a></span>). However, there are many cases of NMS occurring months after stable antipsychotic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12766935']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12766935'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Males (twice as likely to develop NMS compared to females) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9735957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9735957'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• High-dose antipsychotic treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant lithium or benzodiazepine (potential risk factors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Catatonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Polypharmacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Pharmacokinetic interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• IM administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Rapid dosage escalation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Psychomotor agitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Orthostatic hypotension</b> and accompanying <b>dizziness, postural orthostatic tachycardia, </b>and<b> syncope </b>may sometimes occur, particularly with rapid titration and/or in older adults (which may result in subsequent falling and fracture). (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25581312','lexi-content-ref-Gambhir.2014','lexi-content-ref-20706126','lexi-content-ref-30925499','lexi-content-ref-30192094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25581312','lexi-content-ref-Gambhir.2014','lexi-content-ref-20706126','lexi-content-ref-30925499','lexi-content-ref-30192094'])">Ref</a></span>). In addition<b>, tachycardia</b> is common with paliperidone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28140680','lexi-content-ref-30925499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28140680','lexi-content-ref-30925499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Orthostatic hypotension from antipsychotics is attributed to alpha-1 receptor antagonism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30192094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30192094'])">Ref</a></span>). Antipsychotics in patients with schizophrenia are also associated with dysfunction of the autonomic nervous system with a variety sympathetic and parasympathetic effects, resulting in heart rate variability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33903594']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33903594'])">Ref</a></span>). In addition to paliperidone’s alpha-1 receptor antagonism, it can also block presynaptic alpha-2 receptors causing disinhibited norepinephrine release and activation of cardiac sympathetic nerves. However, it can also block histamine-1 and cholinergic receptors (low affinity) resulting in cardiac vagus nerve excitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20706126','lexi-content-ref-23151241','lexi-content-ref-30925499','lexi-content-ref-30271152']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20706126','lexi-content-ref-23151241','lexi-content-ref-30925499','lexi-content-ref-30271152'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; in general, antipsychotic-induced orthostatic hypotension is most common during the initial dose titration but can also occur following subsequent dose increases.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities) or cerebrovascular disease</p>
<p style="text-indent:-2em;margin-left:8em;">• Known predisposing conditions (eg, hypovolemia/dehydration)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant medications that also cause or exacerbate orthostatic hypotension (eg, tricyclic antidepressants, antihypertensive medications)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults</p>
<p style="text-indent:-2em;margin-left:8em;">• Rapid dose titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187598'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">QT prolongation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Paliperidone has been associated with <b>prolonged QT interval on ECG</b>, with a possible risk for torsades de pointes (TdP), predominately in patients with other TdP risk factors or receiving concomitant agents that can prolong the QTc interval and/or increase paliperidone concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26574175','lexi-content-ref-23422378','lexi-content-ref-25168784','lexi-content-ref-21394035']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26574175','lexi-content-ref-23422378','lexi-content-ref-25168784','lexi-content-ref-21394035'])">Ref</a></span>). Of the antipsychotics, paliperidone appears to have a modest to moderate QTc-prolongation effect at therapeutic doses, however, there is limited and conflicting evidence, with some based on paliperidone being a metabolite of risperidone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23295003','lexi-content-ref-33555955','lexi-content-ref-20881844','lexi-content-ref-22410947','lexi-content-ref-23810019','lexi-content-ref-29955530','lexi-content-ref-22144033','lexi-content-ref-22114630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23295003','lexi-content-ref-33555955','lexi-content-ref-20881844','lexi-content-ref-22410947','lexi-content-ref-23810019','lexi-content-ref-29955530','lexi-content-ref-22144033','lexi-content-ref-22114630'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-dependent; paliperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current, although other mechanisms might also be involved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23812796','lexi-content-ref-21394035']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23812796','lexi-content-ref-21394035'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced QTc prolongation/TdP (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure with a reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline QTc interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypokalemia, hypocalcemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Coadministration of multiple medications (≥2) that prolong the QT interval or increase drug interactions that increase serum drug concentrations of QTc prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>). <b>Note: </b>Paliperidone is a metabolite of risperidone and metabolism by CYP450 isoenzymes plays a limited role in its elimination.</p>
<p style="text-indent:-2em;margin-left:8em;">• Substance use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20210726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20210726'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sexual dysfunction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics have been associated with <b>sexual disorders</b> in both males and females. Antipsychotic treatment has been associated with effects on all phases of sexual activity (libido, arousal, and orgasm); however, many patients with schizophrenia experience more frequent sexual dysfunction, with or without antipsychotic treatment. The following adverse reactions have been observed with paliperidone: <b>Decreased libido</b>, <b>erectile dysfunction</b>, and abnormal orgasm (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28660406','lexi-content-ref-20706126','lexi-content-ref-23737244','lexi-content-ref-26780600','lexi-content-ref-28252452']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28660406','lexi-content-ref-20706126','lexi-content-ref-23737244','lexi-content-ref-26780600','lexi-content-ref-28252452'])">Ref</a></span>). In addition, <b>priapism</b> has been reported with paliperidone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32678522','lexi-content-ref-31703010','lexi-content-ref-24740252']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32678522','lexi-content-ref-31703010','lexi-content-ref-24740252'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Antipsychotic-induced sexual dysfunction has been attributed to many potential mechanisms, including dopamine receptor antagonism, dopamine D<sub>2 </sub>receptor antagonism in the infundibular dopaminergic pathway causing hyperprolactinemia, histamine receptor antagonism, cholinergic receptor antagonism, and alpha-adrenergic receptor antagonism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23737244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23737244'])">Ref</a></span>). Of note, paliperidone is associated with a high propensity for hyperprolactinemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23737244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23737244'])">Ref</a></span>). Priapism is believed to be caused by alpha-1 adrenergic antagonism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32678522']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32678522'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Hyperprolactinemia (although a correlation with sexual dysfunction has been observed, a relationship has not been confirmed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23737244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23737244'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Schizophrenia (the prevalence of antipsychotic-induced sexual dysfunction in patients with schizophrenia is high [~50% to 60% compared with 31% of men in the general population]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22533871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22533871'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Based on data with risperidone, paliperidone is likely to be associated with a high prevalence of sexual dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23737244','lexi-content-ref-28252452']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23737244','lexi-content-ref-28252452'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Temperature dysregulation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics may impair the body’s ability to regulate core body temperature, which may cause a potentially life-threatening heat stroke during predisposing conditions, such as heat wave or strenuous exercise. There are also case reports of potentially life-threatening <b>hypothermia </b>associated with paliperidone use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirapara.2020','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirapara.2020','lexi-content-ref-28936184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non–dose-related; idiosyncratic. Exact mechanism is unknown; however, body temperature is regulated by the hypothalamus with involvement of the dopamine, serotonin, and norepinephrine neurotransmitters. D<sub>2 </sub>antagonism may cause an increase in body temperature, while 5-HT<sub>2A</sub> (serotonin) receptor antagonism may cause a decrease in body temperature. Of note, paliperidone has pronounced 5-HT<sub>2A</sub> receptor antagonism, with stronger affinity for 5-HT<sub>2A</sub> receptors than for D<sub>2</sub> receptors. In addition, antagonism of peripheral alpha-adrenergic receptors has also been suggested as a factor in the hypothermic effect by inhibiting peripheral responses to cooling (vasoconstriction and shivering) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirapara.2020','lexi-content-ref-Martinez.2014','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirapara.2020','lexi-content-ref-Martinez.2014','lexi-content-ref-28936184'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Hypothermia: Varied; antipsychotic-induced hypothermia cases indicate a typical onset in the period shortly after initiation of therapy or a dosage increase (first 7 to 10 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17401555','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17401555','lexi-content-ref-28936184'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:6em;">Heat stroke:</p>
<p style="text-indent:-2em;margin-left:8em;">• Psychiatric illness (regardless of medication use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9712220','lexi-content-ref-17698676','lexi-content-ref-18941580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9712220','lexi-content-ref-17698676','lexi-content-ref-18941580'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Strenuous exercise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Heat exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant medications possessing anticholinergic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Hypothermia:</p>
<p style="text-indent:-2em;margin-left:8em;">• In general, predisposing risk factors include: Older adults, cerebrovascular accident, preexisting brain damage, hypothyroidism, malnutrition, shock, sepsis, adrenal insufficiency, diabetes, disability, burns, exfoliative dermatitis benzodiazepine use, alcohol intoxication, kidney or liver failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28936184'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Schizophrenia (regardless of antipsychotic use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17401555']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17401555'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Weight gain</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Paliperidone is associated with significant <b>weight gain </b>(increase of ≥7% from baseline) in adult and pediatric patients, which is a component of the metabolic syndrome observed with this pharmacologic class (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bak.2014','lexi-content-ref-22009159','lexi-content-ref-20706126','lexi-content-ref-23810019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bak.2014','lexi-content-ref-22009159','lexi-content-ref-20706126','lexi-content-ref-23810019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Multiple proposed mechanisms, including actions at serotonin, dopamine, histamine, and muscarinic receptors, with differing effects explained by differing affinity of antipsychotics at these receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731','lexi-content-ref-26218604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731','lexi-content-ref-26218604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; antipsychotic-induced weight gain usually occurs rapidly in the initial period following initiation, then gradually decreases and flattens over several months with patients continuing to gain weight in the long term (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Family history of obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Parental BMI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159','lexi-content-ref-15998156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159','lexi-content-ref-15998156'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Rapid weight gain in the initial period: Younger age, lower baseline BMI, more robust response to antipsychotic, and increase in appetite; rapid weight gain of &gt;5% in the first month has been observed as the best predictor for significant long-term weight gain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Duration of therapy (although weight gain plateaus, patients continue to gain weight over time) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Schizophrenia (regardless of medication) is associated with a higher prevalence of obesity compared to the general population due to components of the illness, such as negative symptoms, sedentary lifestyles, and unhealthy diets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861176'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Paliperidone:</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific antipsychotic: Paliperidone is considered to have an intermediate/moderate propensity for causing weight gain; olanzapine and clozapine are associated with a high risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731','lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731','lexi-content-ref-22009159'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F3982386"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Unless otherwise noted, frequency of adverse effects is reported for both the oral and IM formulations.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Tachycardia (1% to 14%)<span class="lexi-table-link-container"> (<a aria-label="Tachycardia table link" class="lexi-table-link" data-table-id="lexi-content-tachycardia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-tachycardia')">table 1</a>)</span><span class="table-link" style="display:none;">Tachycardia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Tachycardia" frame="border" id="lexi-content-tachycardia" rules="all">
<caption style="text-align:center;">
<b>Paliperidone: Adverse Reaction: Tachycardia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">45</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">35</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 to 6 mg once-daily fixed-dose range</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizoaffective disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">108</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">202</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 to 12 mg once-daily flexible dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizoaffective disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">214</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">202</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9 to 12 mg once-daily fixed-dose range</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizoaffective disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">202</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">127</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">242</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">246</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased HDL cholesterol (IM: 10% to 16%; oral: 7% to 29%)<span class="lexi-table-link-container"> (<a aria-label="Decreased HDL Cholesterol table link" class="lexi-table-link" data-table-id="lexi-content-decreased-hdl-cholesterol" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-decreased-hdl-cholesterol')">table 2</a>)</span><span class="table-link" style="display:none;">Decreased HDL Cholesterol</span>, hyperglycemia (≤11%)<span class="lexi-table-link-container"> (<a aria-label="Hyperglycemia table link" class="lexi-table-link" data-table-id="lexi-content-hyperglycemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hyperglycemia')">table 3</a>)</span><span class="table-link" style="display:none;">Hyperglycemia</span>, increased LDL cholesterol (IM: &lt;1%; oral: 4% to 14%), increased serum cholesterol (≤11%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Cholesterol table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-cholesterol" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-cholesterol')">table 4</a>)</span><span class="table-link" style="display:none;">Increased Serum Cholesterol</span>, increased serum prolactin (females: 30% to 51%; males: 35% to 56%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Prolactin table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-prolactin" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-prolactin')">table 5</a>)</span><span class="table-link" style="display:none;">Increased Serum Prolactin</span>, increased serum triglycerides (1% to 13%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Triglycerides table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-triglycerides" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-triglycerides')">table 6</a>)</span><span class="table-link" style="display:none;">Increased Serum Triglycerides</span>, weight gain (2% to 19%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Decreased HDL Cholesterol" frame="border" id="lexi-content-decreased-hdl-cholesterol" rules="all">
<caption style="text-align:center;">
<b>Paliperidone: Adverse Reaction: Decreased HDL Cholesterol</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">28</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">22</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">28</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">23</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">28</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.5 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">28</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">134</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">137</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">135</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">80</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">234/234 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">81</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">203</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">39 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">61</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">203</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">156 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">106</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">203</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">127</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">194</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-six-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">423</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">234/39 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">71</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">203</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">234/156 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">203</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">115</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">203</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hyperglycemia" frame="border" id="lexi-content-hyperglycemia" rules="all">
<caption style="text-align:center;">
<b>Paliperidone: Adverse Reaction: Hyperglycemia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">27</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">32</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.5 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">34</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">32</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">32</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">32</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">234/156 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">234/234 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">39 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">64</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">173</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">156</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">236</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">187</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">236</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-six-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">423</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">128</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">156 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">154</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">157</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">236</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">195</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">234/39 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">79</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">241</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">93</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">236</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Cholesterol" frame="border" id="lexi-content-increased-serum-cholesterol" rules="all">
<caption style="text-align:center;">
<b>Paliperidone: Adverse Reaction: Increased Serum Cholesterol</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">27</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;170 mg/dL to ≥200 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">27</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;170 mg/dL to ≥200 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.5 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">26</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">27</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;170 mg/dL to ≥200 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">27</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;170 mg/dL to ≥200 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">234/234 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">84</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">222</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;200 mg/dL to ≥240 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">125</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">194</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;200 mg/dL to ≥240 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">147</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">194</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;200 mg/dL to ≥240 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">71</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">194</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;200 mg/dL to ≥240 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">130</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">194</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;200 mg/dL to ≥240 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">234/156 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">65</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">222</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;200 mg/dL to ≥240 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">39 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">222</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;200 mg/dL to ≥240 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">147</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">222</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;200 mg/dL to ≥240 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">156 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">141</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">222</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;200 mg/dL to ≥240 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">194</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;200 mg/dL to ≥240 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">128</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;200 mg/dL to ≥240 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-six-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">423</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;200 mg/dL to ≥240 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">234/39 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">69</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">222</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;200 mg/dL to ≥240 mg/dL</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Prolactin" frame="border" id="lexi-content-increased-serum-prolactin" rules="all">
<caption style="text-align:center;">
<b>Paliperidone: Adverse Reaction: Increased Serum Prolactin</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">44%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizoaffective disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;26.72 ng/mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">51%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">43%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;30 ng/mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">32%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;26.72 ng/mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">30%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;26.72 ng/mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-six-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;26.72 ng/mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">56%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizoaffective disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;13.13 ng/mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">52%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;18 ng/mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">46%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;13.13 ng/mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">36%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;13.13 ng/mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-six-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;13.13 ng/mL</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Triglycerides" frame="border" id="lexi-content-increased-serum-triglycerides" rules="all">
<caption style="text-align:center;">
<b>Paliperidone: Adverse Reaction: Increased Serum Triglycerides</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">34</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">26</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">34</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">28</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">34</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.5 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">38</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">34</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">82</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">208</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">234/234 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">84</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">221</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">194</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">136</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">208</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">150</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">208</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">153</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">221</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">128</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">156 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">139</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">221</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">39 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">49</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">221</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-six-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">423</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">139</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">208</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">234/156 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">82</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">221</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">234/39 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">79</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">221</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (5% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (IM: ≤13%), induration at injection site (≤13%), injection-site reaction (IM: 3% to 11%; including pain at injection site), swelling at injection site (IM: ≤13%), tenderness at injection site (IM: 31%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Akathisia (1% to 17%)<span class="lexi-table-link-container"> (<a aria-label="Akathisia table link" class="lexi-table-link" data-table-id="lexi-content-akathisia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-akathisia')">table 7</a>)</span><span class="table-link" style="display:none;">Akathisia</span>, drowsiness (≤26%), dystonia (1% to 14%)<span class="lexi-table-link-container"> (<a aria-label="Dystonia table link" class="lexi-table-link" data-table-id="lexi-content-dystonia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dystonia')">table 8</a>)</span><span class="table-link" style="display:none;">Dystonia</span>, extrapyramidal reaction (IM: 2% to 12%; oral: 4% to 40%; including torticollis, trismus), headache (6% to 15%), parkinsonism (2% to 18%; including parkinsonian gait), tremor (IM: ≤1%; oral: 2% to 12%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Akathisia" frame="border" id="lexi-content-akathisia" rules="all">
<caption style="text-align:center;">
<b>Paliperidone: Adverse Reaction: Akathisia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">35</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">45</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.5 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">54</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9 to 12 mg once-daily fixed-dose range</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizoaffective disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">202</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 to 12 mg once-daily flexible dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizoaffective disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">214</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">202</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 to 6 mg once-daily fixed-dose range</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizoaffective disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">108</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">202</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">242</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">242</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">246</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">246</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">223</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">234/234 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">163</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">510</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">127</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">160</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">145</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">39 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">130</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">156 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">228</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">234/156 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">165</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">510</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">127</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">160</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">145</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">224</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-six-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">478</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-six-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">478</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">224</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">156 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">312</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">510</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">39 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">130</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">510</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">302</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">510</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">234/39 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">160</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">510</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dystonia" frame="border" id="lexi-content-dystonia" rules="all">
<caption style="text-align:center;">
<b>Paliperidone: Adverse Reaction: Dystonia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">35</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">45</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.5 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">54</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9 to 12 mg once-daily fixed-dose range</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizoaffective disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">202</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 to 6 mg once-daily fixed-dose range</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizoaffective disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">108</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">202</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 to 12 mg once-daily flexible dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizoaffective disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">214</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">202</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">246</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">242</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">156 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">228</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-six-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">478</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">224</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">127</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">160</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">145</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">39 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">130</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">223</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hyperkinetic muscle activity (IM: 4% to 5%; oral: 4% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (2% to 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (&lt;2%), bundle branch block (3%), edema (oral: &lt;2%), first-degree atrioventricular block (2%), hypertension (2%), orthostatic hypotension (IM: &lt;1%; oral: 2% to 4%), palpitations (&lt;2%), sinoatrial nodal rhythm disorder (oral: ≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (&lt;2%), skin rash (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea (2% to 6%)<span class="lexi-table-link-container"> (<a aria-label="Amenorrhea table link" class="lexi-table-link" data-table-id="lexi-content-amenorrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-amenorrhea')">table 9</a>)</span><span class="table-link" style="display:none;">Amenorrhea</span>, decreased libido (IM: 1%)<span class="lexi-table-link-container"> (<a aria-label="Decreased Libido table link" class="lexi-table-link" data-table-id="lexi-content-decreased-libido" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-decreased-libido')">table 10</a>)</span><span class="table-link" style="display:none;">Decreased Libido</span>, galactorrhea not associated with childbirth (1% to 4%)<span class="lexi-table-link-container"> (<a aria-label="Galactorrhea not Associated with Childbirth table link" class="lexi-table-link" data-table-id="lexi-content-galactorrhea-not-associated-with-childbirth" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-galactorrhea-not-associated-with-childbirth')">table 11</a>)</span><span class="table-link" style="display:none;">Galactorrhea not Associated with Childbirth</span>, gynecomastia (3%)<span class="lexi-table-link-container"> (<a aria-label="Gynecomastia table link" class="lexi-table-link" data-table-id="lexi-content-gynecomastia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-gynecomastia')">table 12</a>)</span><span class="table-link" style="display:none;">Gynecomastia</span>, irregular menses (&lt;2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Amenorrhea" frame="border" id="lexi-content-amenorrhea" rules="all">
<caption style="text-align:center;">
<b>Paliperidone: Adverse Reaction: Amenorrhea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizoaffective disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Decreased Libido" frame="border" id="lexi-content-decreased-libido" rules="all">
<caption style="text-align:center;">
<b>Paliperidone: Adverse Reaction: Decreased Libido</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizoaffective disorder</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizoaffective disorder</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Galactorrhea not Associated with Childbirth" frame="border" id="lexi-content-galactorrhea-not-associated-with-childbirth" rules="all">
<caption style="text-align:center;">
<b>Paliperidone: Adverse Reaction: Galactorrhea not Associated with Childbirth</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">45</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizoaffective disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Gynecomastia" frame="border" id="lexi-content-gynecomastia" rules="all">
<caption style="text-align:center;">
<b>Paliperidone: Adverse Reaction: Gynecomastia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">35</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (≤4%), constipation (4% to 5%), decreased appetite (1% to 2%), diarrhea (IM: 2% to 3%), dyspepsia (5% to 6%), flatulence (&lt;2%), increased appetite (2% to 3%), nausea (4% to 8%), sialorrhea (1% to 6%), stomach discomfort (2%), tongue paralysis (oral: 3%), upper abdominal pain (≤4%), xerostomia (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast tenderness (&lt;2%), erectile dysfunction (IM: ≤1%)<span class="lexi-table-link-container"> (<a aria-label="Erectile Dysfunction table link" class="lexi-table-link" data-table-id="lexi-content-erectile-dysfunction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-erectile-dysfunction')">table 13</a>)</span><span class="table-link" style="display:none;">Erectile Dysfunction</span>, retrograde ejaculation (oral: &lt;2%), urinary tract infection (≤3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Erectile Dysfunction" frame="border" id="lexi-content-erectile-dysfunction" rules="all">
<caption style="text-align:center;">
<b>Paliperidone: Adverse Reaction: Erectile Dysfunction</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizoaffective disorder</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (&lt;2%), increased serum aspartate aminotransferase (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (&lt;2%), swollen tongue (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (IM: 8% to 10%; oral: &lt;2%), anxiety (3% to 9%), asthenia (≤4%), dizziness (1% to 6%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 14</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, dysarthria (1% to 4%), fatigue (2% to 4%), insomnia (≤3%), lethargy (3%), nightmares (≤2%), opisthotonus (oral: &lt;2%), psychosis (3%), sedated state (≤7%), sleep disorder (oral: 2% to 3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Paliperidone: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">35</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.5 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">54</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">45</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">127</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">39 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">130</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">510</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">242</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">246</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">156 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">312</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">510</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">234/156 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">165</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">510</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">302</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">510</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">234/234 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">163</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">510</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">234/39 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">160</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">510</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (&lt;2%), back pain (3%), dyskinesia (1% to 9%)<span class="lexi-table-link-container"> (<a aria-label="Dyskinesia table link" class="lexi-table-link" data-table-id="lexi-content-dyskinesia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dyskinesia')">table 15</a>)</span><span class="table-link" style="display:none;">Dyskinesia</span>, limb pain (≤3%), muscle rigidity (2%), musculoskeletal pain (3%), myalgia (1% to 4%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dyskinesia" frame="border" id="lexi-content-dyskinesia" rules="all">
<caption style="text-align:center;">
<b>Paliperidone: Adverse Reaction: Dyskinesia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">35</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1.5 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">54</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">45</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">51</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 to 6 mg once-daily fixed-dose range</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizoaffective disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">108</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">202</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9 to 12 mg once-daily fixed-dose range</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizoaffective disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">202</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 to 12 mg once-daily flexible dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizoaffective disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">214</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">202</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">242</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">246</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">223</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">127</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">39 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">130</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">156 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">228</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">235</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">160</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">145</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">223</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-six-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">478</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">39 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">130</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-six-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">478</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">224</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">224</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Every-three-month extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">160</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">145</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">156 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">228</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Abnormal eye movements (&lt;2%; includes eye rolling), blurred vision (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (2% to 3%), epistaxis (oral: 2%), nasal congestion (&lt;2%), nasopharyngitis (2% to 5%), pharyngolaryngeal pain (oral: 1% to 2%), rhinitis (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Cardiovascular: Prolonged QT interval on ECG, syncope<span class="lexi-table-link-container"> (<a aria-label="Syncope table link" class="lexi-table-link" data-table-id="lexi-content-syncope" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-syncope')">table 16</a>)</span><span class="table-link" style="display:none;">Syncope</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Syncope" frame="border" id="lexi-content-syncope" rules="all">
<caption style="text-align:center;">
<b>Paliperidone: Adverse Reaction: Syncope</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Paliperidone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">850</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">355</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Once-monthly extended-release injectable suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,293</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">510</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (any formulation):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Postural orthostatic tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Oromandibular dystonia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast engorgement, breast swelling, cystitis, priapism</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Fixed drug eruption, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cogwheel rigidity, depression, drooling, psychomotor agitation, restlessness, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Joint stiffness, muscle spasm, muscle twitching</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Tonsillitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any formulation):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: ECG abnormality (Stroup 2018), orthostatic dizziness (Stroup 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Toxic epidermal necrolysis (injection) (Struye 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus (Sliwa 2014), hyperinsulinism (Omi 2016), hyponatremia (Solmi 2017) (menstrual disease (Savitz 2015, Seo 2020), SIADH (Mazhar 2020), weight loss (Seo 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysphagia (Crouse 2018), intestinal obstruction</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast hypertrophy (Savitz 2015), ejaculatory disorder (Savitz 2015), mastalgia (Gopal 2017, Savitz 2015), nipple discharge (Gopal 2017, Savitz 2015), sexual disorder (Harrington 2010, Mauri 2017), urinary incontinence (Karslıoǧlu 2016), urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Wakuda 2019), leukopenia (Kim 2011), neutropenia (Kim 2011), thrombotic thrombocytopenic purpura</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Papadopoulou 2017), nonimmune anaphylaxis (Perry 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal sensory symptoms (sensory instability), catatonia (McKeown 2010), cerebrovascular accident (Solmi 2017), hypertonia (Seo 2020), hypothermia (Hirapara 2019), neuroleptic malignant syndrome (Nayak 2011), seizure (Stroup 2018), somnambulism, tic disorder (Hsieh 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bradykinesia (Solmi 2017), tardive dyskinesia (Wei 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Oculogyric crisis (Seo 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory tract infection (Harrington 2010, Mauri 2017)</p></div>
<div class="block coi drugH1Div" id="F3982382"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (anaphylaxis, angioedema) to paliperidone, risperidone, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F3982383"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Falls: May increase the risk for falls due to somnolence, orthostatic hypotension, and motor or sensory instability.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with kidney disease; dosage adjustment recommendations vary based on formulation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications that may lower seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predisposing factors.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extended-release tablet: Use is not recommended in patients with preexisting severe GI-narrowing disorders (nondeformable controlled-release formulation). Patients with upper GI tract alterations in transit time may have increased or decreased bioavailability of paliperidone. Formulation consists of drug within a nonabsorbable shell; following drug release/absorption, the shell is expelled in the stool.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>
<b>Other warnings/precautions</b>:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: When discontinuing antipsychotic therapy, gradually taper antipsychotics to avoid physical withdrawal symptoms and rebound symptoms (APA [Keepers 2020]; WFSBP [Hasan 2012]). Withdrawal symptoms may include agitation, alternating feelings of warmth and cold, anxiety, diaphoresis, dyskinesia, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor and vertigo (Lambert 2007; Moncrieff 2020). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anticholinergic or dopaminergic antipsychotics (Cerovecki 2013). Patients with chronic symptoms, repeated relapses, and clear diagnostic features of schizophrenia are at risk for poor outcomes if medications are discontinued (APA [Keepers 2020]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878710"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Risk of dystonia is increased with the use of high potency and higher doses of conventional antipsychotics and in males and younger patients; occurring in up to 18% of children.</p>
<p style="text-indent:0em;margin-top:2em;">Long-term usefulness of paliperidone should be periodically re-evaluated in patients receiving the drug for extended periods of time. Invega is an extended-release tablet based on the OROSA osmotic delivery system. Water from the GI tract enters through a semipermeable membrane coating the tablet, solubilizing the drug into a gelatinous form which, through hydrophilic expansion, is then expelled through laser-drilled holes in the coating.</p>
<p style="text-indent:0em;margin-top:2em;">Similar to adult experience, the American Academy of Child and Adolescent Psychiatry (AACAP) guidelines recommend gradually tapering antipsychotics to avoid withdrawal symptoms and minimize the risk of relapse (AACAP [McClellan 2007]).</p></div>
<div class="block foc drugH1Div" id="F3982430"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Intramuscular, as palmitate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Invega Trinza: 410 mg/1.315 mL (1.315 mL); 273 mg/0.875 mL (0.875 mL); 546 mg/1.75 mL (1.75 mL); 819 mg/2.625 mL (2.625 mL) [contains polyethylene glycol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Prefilled Syringe, Intramuscular, as palmitate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Invega Hafyera: 1092 mg/3.5 mL (3.5 mL); 1560 mg/5 mL (5 mL) [contains polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Invega Sustenna: 39 mg/0.25 mL (0.25 mL); 78 mg/0.5 mL (0.5 mL); 117 mg/0.75 mL (0.75 mL); 156 mg/mL (1 mL); 234 mg/1.5 mL (1.5 mL) [contains polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Invega: 1.5 mg [DSC], 3 mg, 6 mg, 9 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1.5 mg, 3 mg, 6 mg, 9 mg</p></div>
<div class="block geq drugH1Div" id="F3981434"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F5165183"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Prefilled Syringe</b> (Invega Hafyera Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1092MG/3.5ML (per mL): $4,552.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1560 mg/5 mL (per mL): $4,779.94</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Prefilled Syringe</b> (Invega Sustenna Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">39 mg/0.25 mL (per 0.25 mL): $669.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">78 mg/0.5 mL (per 0.5 mL): $1,339.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">117 mg/0.75 mL (per 0.75 mL): $2,008.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">156 mg/mL (per mL): $2,678.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">234 mg/1.5 mL (per mL): $2,678.49</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Prefilled Syringe</b> (Invega Trinza Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">273MG/0.88ML (per 0.88 mL): $4,017.62</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">410MG/1.32ML (per mL): $4,565.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">546MG/1.75ML (per mL): $4,591.82</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">819MG/2.63ML (per mL): $4,582.99</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Invega Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $14.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg (per each): $14.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">9 mg (per each): $22.07</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Paliperidone ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 mg (per each): $14.67 - $30.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $14.67 - $30.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg (per each): $14.67 - $30.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">9 mg (per each): $22.00 - $45.89</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868845"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Prefilled Syringe, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Invega Sustenna: 50 mg/0.5 mL (0.5 mL); 75 mg/0.75 mL (0.75 mL); 100 mg/mL (1 mL); 150 mg/1.5 mL (1.5 mL) [contains polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Invega Trinza: 175 mg/0.875 mL (0.875 mL); 263 mg/1.315 mL (1.315 mL); 350 mg/1.75 mL (1.75 mL); 525 mg/2.625 mL (2.625 mL) [contains polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Invega: 3 mg, 6 mg, 9 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 3 mg, 6 mg</p></div>
<div class="block admp drugH1Div" id="F52614229"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer in the morning without regard to meals; swallow extended-release tablets whole with liquids; do not crush, chew, or divide.</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Administer only as a single injection (do not divide); do not administer by any other route. Avoid inadvertent injection into vasculature.</p>
<p style="text-indent:-2em;margin-left:4em;">Monthly paliperidone (Invega Sustenna): Do not mix with any other product or diluent. Prior to injection, shake syringe for <b>at least 10 seconds</b> to ensure a homogenous suspension. Administer using only the needles that are provided in the kit. The 2 initial injections should be administered in the deltoid muscle using a 1<sup>1</sup>/<sub>2</sub>-inch, 22-gauge needle for patients ≥90 kg, and a 1-inch, 23-gauge needle for patients &lt;90 kg. The two initial deltoid intramuscular injections help attain therapeutic concentrations rapidly. Alternate deltoid injections (right and left deltoid muscle). The second dose may be administered 4 days before or after the weekly time point. Monthly maintenance doses can be administered in either the deltoid or gluteal muscle. Administer injections in the gluteal muscle using a 1<sup>1</sup>/<sub>2</sub>-inch, 22-gauge needle (regardless of patient weight) in the upper-outer quadrant of the gluteal area. Alternate gluteal injections (right and left gluteal muscle). The monthly maintenance dose may be administered 7 days before or after the monthly time point.</p>
<p style="text-indent:-2em;margin-left:4em;">Three-month paliperidone (Invega Trinza): Should only be administered by a health care professional. Prior to injection, shake syringe with tip pointing up for <b>at least 15 seconds</b> to ensure a homogenous suspension. <b>Inject within 5 minutes of shaking vigorously.</b> Inject slowly, deep into the deltoid or gluteal muscle. Must be administered using only the thin wall needles that are provided in the pack. Do <b>not</b> use needles from monthly IM paliperidone or other commercially available needles to reduce the risk of blockage. Administer into the center of the deltoid muscle using a 1<sup>1</sup>/<sub>2</sub>-inch, 22-gauge thin wall needle for patients ≥90 kg, and a 1-inch, 22-gauge thin wall needle for patients &lt;90 kg. Alternate deltoid injections (right and left deltoid muscle). Administer injections in the gluteal muscle using a 1<sup>1</sup>/<sub>2</sub>-inch, 22-gauge thin wall needle (regardless of patient weight) in the upper-outer quadrant of the gluteal area. Alternate gluteal injections (right and left gluteal muscle). In the event of an incompletely administered dose, do not re-inject the dose remaining in the syringe and do not administer another dose. Closely monitor and treat the patient with oral supplementation as clinically appropriate until the next scheduled 3-month injection.</p>
<p style="text-indent:-2em;margin-left:4em;">Six-month paliperidone (Invega Hafyera): Prior to injection, shake syringe with tip pointing up very fast for at least 15 seconds. Rest briefly, then shake again for 15 seconds to ensure a homogenous suspension. Inject within 5 minutes of shaking vigorously; resuspend by shaking for ≥30 seconds if &gt;5 minutes pass before injection. Inject slowly (over ~30 seconds), deep into the gluteal muscle. Must be administered using only the thin wall needles that are provided in the pack. Do not use needles from monthly IM paliperidone, 3-month IM paliperidone, or other commercially available needles to reduce the risk of blockage. Administer using the provided 1<sup>1</sup>/<sub>2</sub>-inch, 20-gauge thin wall needle, regardless of patient weight, in the upper-outer quadrant of the gluteal area; alternate injections between right and left gluteal muscle. In the event of an incompletely administered dose, do not reinject the dose remaining in the syringe and do not administer another dose.</p></div>
<div class="block adm drugH1Div" id="F3982415"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer without regard to meals. ER tablets should be swallowed whole with liquids; do not crush, chew, or divide.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. An IM formulation of Invega is available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, close clinical monitoring is advised in the immediate postoperative phase for the theoretical circumstance of reduced absorption after bariatric surgery.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM injection:</b> Administer by IM route only as a single injection (do not divide); do not administer by any other route. Do not mix with any other product or diluent. Avoid inadvertent injection into vasculature.</p>
<p style="text-indent:-2em;margin-left:4em;">Monthly paliperidone (Invega Sustenna): Prior to injection, shake syringe for <b>at least 10 seconds</b> to ensure a homogenous suspension. Administer using only the needles that are provided in the kit. The 2 initial injections should be administered in the deltoid muscle using a 1<sup>1</sup>/<sub>2</sub> inch, 22-gauge needle for patients ≥90 kg, and a 1 inch, 23-gauge needle for patients &lt;90 kg. The 2 initial deltoid intramuscular injections help attain therapeutic concentrations rapidly. Alternate deltoid injections (right and left deltoid muscle). The second dose may be administered 4 days before or after the weekly time point. Monthly maintenance doses can be administered in either the deltoid or gluteal muscle. Administer injections in the gluteal muscle using a 1<sup>1</sup>/<sub>2</sub> inch, 22-gauge needle (regardless of patient weight) in the upper-outer quadrant of the gluteal area. Alternate gluteal injections (right and left gluteal muscle).</p>
<p style="text-indent:-2em;margin-left:4em;">Three-month paliperidone (Invega Trinza): Prior to injection, shake syringe for with tip pointing up <b>at least 15 seconds</b> to ensure a homogenous suspension. <b>Inject within 5 minutes of shaking vigorously.</b> Inject slowly, deep into the deltoid or gluteal muscle. Must be administered using only the thin wall needles that are provided in the pack. Do <b>not</b> use needles from monthly IM paliperidone or other commercially available needles to reduce the risk of blockage. Administer into the center of the deltoid muscle using a 1<sup>1</sup>/<sub>2</sub> inch, 22-gauge thin wall needle for patients ≥90 kg, and a 1 inch, 22-gauge thin wall needle for patients &lt;90 kg. Alternate deltoid injections (right and left deltoid muscle). Administer injections in the gluteal muscle using a 1<sup>1</sup>/<sub>2</sub> inch, 22-gauge thin wall needle (regardless of patient weight) in the upper-outer quadrant of the gluteal area. Alternate gluteal injections (right and left gluteal muscle). In the event of an incompletely administered dose, do not re-inject the dose remaining in the syringe and do not administer another dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Six-month paliperidone (Invega Hafyera): Prior to injection, shake syringe with tip pointing up <b>very fast for at least 15 seconds</b>. Rest briefly, then shake again for 15 seconds to ensure a homogenous suspension. <b>Inject within 5 minutes of shaking vigorously;</b> resuspend by shaking for ≥30 seconds if &gt;5 minutes pass before injection. Inject slowly (over ~30 seconds), deep into the gluteal muscle. Must be administered using only the thin wall needles that are provided in the pack. Do <b>not</b> use needles from monthly IM paliperidone, 3-month IM paliperidone, or other commercially available needles to reduce the risk of blockage. Administer using a 1½ inch, 20-gauge thin-wall needle, regardless of patient weight, in the upper-outer quadrant of the gluteal area; alternate injections between right and left gluteal muscle. In the event of an incompletely administered dose, do not reinject the dose remaining in the syringe and do not administer another dose.</p></div>
<div class="block sts drugH1Div" id="F3982397"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Oral, Monthly IM: Store at ≤25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect tablets from moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">3- and 6-month IM: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not mix with any other product or diluent. Store the 6-month IM product in a horizontal position.</p></div>
<div class="block usep drugH1Div" id="F53570129"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Treatment of schizophrenia (FDA approved in ages ≥12 years and adults); treatment of schizoaffective disorder as monotherapy or adjunctive therapy to mood stabilizers and/or antidepressants (FDA approved in adults); has also been used for treatment of irritability associated with autistic disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Treatment of schizophrenia and schizoaffective disorder (monotherapy) and as adjunct to mood stabilizer and antidepressants (Invega Sustenna: FDA approved in ages ≥18 years and adults); treatment of schizophrenia in patients adequately treated for 4 months with the 1-month paliperidone extended-release formulation (Invega Trinza: FDA approved in ages ≥18 years and adults); treatment of schizophrenia in patients adequately treated for 4 months with 1-month paliperidone extended-release formulation or for at least 1 cycle of the every-3-month paliperidone extended-release formulation (Invega Hafyera: FDA approved in ages ≥18 years and adults).</p></div>
<div class="block mst drugH1Div" id="F14087817"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Invega may be confused with Intuniv</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older due to an increased risk of stroke and a greater rate of cognitive decline and mortality in patients with dementia. Evidence also suggests there may be an increased risk of mortality with use independent of dementia Avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. Use of antipsychotics may be appropriate for labeled indications including schizophrenia, bipolar disorder, Parkinson disease psychosis, adjunctive therapy in major depressive disorder, or for short-term use as an antiemetic (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9838448"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F3982393"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents With Seizure Threshold Lowering Potential: May enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk of neuroleptic malignant syndrome or increased QTc interval may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Amisulpride (Oral). Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (Second Generation [Atypical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Consider avoiding atypical antipsychotic use in patients with Parkinson disease. If an atypical antipsychotic is necessary, consider using clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabergoline: May diminish the therapeutic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ChlorproMAZINE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Donepezil: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Flupentixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Galantamine: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Haloperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Huperzine A: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inducers of CYP3A4 (Strong) and P-glycoprotein: May decrease the serum concentration of Paliperidone. Management: Monitor for reduced paliperidone effects when combined with strong inducers of both CYP3A4 and P-gp. Avoid use of these inducers with extended-release injectable paliperidone and instead manage patients with paliperidone extended-release tablets.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Levoketoconazole.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to one of these agents when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of OLANZapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pimozide. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents.  Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prochlorperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of QUEtiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: May enhance the adverse/toxic effect of Paliperidone. Management: Additive paliperidone exposure is expected with this combination.  Consider using an alternative combination when possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sertindole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Paliperidone. Management: Monitor for reduced paliperidone effects when combined St. John's wort. Avoid use of St. John's wort with extended-release injectable paliperidone and instead manage patients with paliperidone extended-release tablets.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for NMS and extrapyramidal symptoms may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thioridazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triptorelin: Hyperprolactinemic Agents may diminish the therapeutic effect of Triptorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May increase the serum concentration of Paliperidone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Ziprasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F51792606"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Paliperidone may cause hyperprolactinemia, which may cause a reversible decrease in fertility in females.</p></div>
<div class="block pri drugH1Div" id="F3982379"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Information specific to paliperidone in pregnancy is limited (Onken 2018; Özdemir 2015; Zamora Rodriguez 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Antipsychotic use during the third trimester of pregnancy has a risk for extrapyramidal symptoms (EPS) and/or withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor. These effects may be self-limiting and allow recovery within hours or days with no specific treatment, or they may be severe requiring prolonged hospitalization.</p>
<p style="text-indent:0em;margin-top:2em;">The ACOG recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy is limited and routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to a typical antipsychotic that the fetus has not yet been exposed to; consider risk:benefit (ACOG 2008).</p>
<p style="text-indent:0em;margin-top:2em;">Paliperidone is the active metabolite of risperidone; refer to Risperidone monograph for additional information.</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers are encouraged to enroll women 18 to 45 years of age exposed to paliperidone during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or http://womensmentalhealth.org/research/pregnancyregistry/).</p></div>
<div class="block mopp drugH1Div" id="F53570124"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure (including orthostatic) and heart rate, particularly during dosage titration; mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms; growth, BMI, waist circumference, and weight (in adults, weight should be assessed prior to treatment, at 4 weeks, 8 weeks, 12 weeks, and then at quarterly intervals; consider titrating to a different antipsychotic agent for a weight gain ≥5% of the initial weight); CBC with differential; liver enzymes in children (especially children who are obese or who are rapidly gaining weight while receiving therapy); lipid profile; fasting blood glucose/HbA<sub>1c</sub> (prior to treatment, at 3 months, then annually); prolactin serum concentrations. <b>Note:</b> Some experts suggest biannual monitoring of cardiometabolic indices (eg, serum cholesterol, triglycerides) (Correll 2009).</p></div>
<div class="block pha drugH1Div" id="F3982398"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Paliperidone is considered a benzisoxazole atypical antipsychotic as it is the primary active metabolite of risperidone. As with other atypical antipsychotics, its therapeutic efficacy is believed to result from mixed central serotonergic and dopaminergic antagonism. The addition of serotonin antagonism to dopamine antagonism (classic neuroleptic mechanism) is thought to improve negative symptoms of psychoses and reduce the incidence of extrapyramidal side effects (Huttunen 1995). Similar to risperidone, paliperidone demonstrates high affinity to α<sub>1</sub>, α<sub>2</sub>, D<sub>2</sub>, H<sub>1</sub>, and 5-HT<sub>2A</sub> receptors and low affinity for muscarinic receptors. In contrast to risperidone, paliperidone displays nearly 10-fold lower affinity for α<sub>2</sub> and 5-HT<sub>2A</sub> receptors, and nearly three- to fivefold less affinity for 5-HT<sub>1A</sub> and 5-HT<sub>1D</sub>, respectively.</p></div>
<div class="block phk drugH1Div" id="F3982400"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Pharmacokinetic parameters in adolescent patients weighing &gt;51 kg were similar to adults; an increased drug exposure (23%) was observed in adolescent patient weighing &lt;51 kg compared to adults and was not considered clinically significant.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Oral: Initial effects may be observed within 1 to 2 weeks of treatment with continued improvements through 4 to 6 weeks (Agid 2003; Levine 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: IM: Slow release (Monthly: Begins on day 1 and continues up to 126 days; 3- and 6-month: Begins on day 1 and continues up to 18 months).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Oral: 487 L; Monthly IM: 391 L; 3- and 6-month IM: 1,960 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 74%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP2D6 and 3A4 (limited role in elimination); minor metabolism (&lt;10% each) via dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 28%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 23 hours; 24 to 51 hours with renal impairment (CrCl &lt;80 mL/minute).</p>
<p style="text-indent:-2em;margin-left:4em;">Monthly IM (following a single-dose administration): Range: 25 to 49 days.</p>
<p style="text-indent:-2em;margin-left:4em;">3-month IM: Deltoid injection range: 84 to 95 days; Gluteal injection range: 118 to 139 days.</p>
<p style="text-indent:-2em;margin-left:4em;">6-month IM (following a single-dose administration): Gluteal injection range: 148 to 159 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Oral: ~24 hours; Monthly IM: 13 days; 3-month IM: 30 to 33 days; 6-month IM: 29 to 32 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (80%; 59% as unchanged drug); feces (11%).</p></div>
<div class="block phksp drugH1Div" id="F51192043"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Elimination of paliperidone decreased with decreasing estimated creatinine clearance.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Slower monthly IM absorption observed in women.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539984"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Invega sustenna | Trevicta</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Invega sustenna | Invega trinza</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Palibon | Paliperidon ratiopharm | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Invega hafyera | Invega sustenna | Invega trinza</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Palimax er</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Byannli | Paliperidon krka | Paliperidone teva | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Egoropal | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Invega sustenna | Invega trinza</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Invega | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Invega sustenna</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Invega sustenna | Invega trinza</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Egoropal | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Paliperidon advanz pharma | Paliperidon ratiopharm | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Invega sustenna</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Invega sustenna</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Xeplion</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Invega | Invega sustenna | Paliper</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Baceq | Byannli | Paliperidona teva | Palmeux | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Paliperidone ratiopharm | Palmeux | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Paliperidone biogaran | Paliperidone teva | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Byannli | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Invega sustenna | Invega trinza</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Paliperidone Janssen | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Egoropal | Paliperidon teva | Parnido | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Invega sustenna | Invega trinza</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Paliperidone krka | Paliperidone teva | Palmeux | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Invega sustenna | Palido od | Palip xr | Paliris | Palivega</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Paliperidone krka | Paliperidone teva italia | Palmeux | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Invega sustenna</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Xeplion</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Trevicta</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Invega er | Invega sustenna | Invega trinza | Palispen er</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Invega sustenna | Trevicta</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Invega sustenna | Trevicta</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Byannli | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Xeplion</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Inveda sustenna | Inveda trinza | Invega trinza</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Invega sustenna | Invega trinza</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Invega | Invega sustenna</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Byannli | Palmeux | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Palmeux | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Invega sustenna | Invega trinza</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Invega sustenna</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Invega | Invega sustenna | Invega trinza</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Avega | Palidone er | Paligit xr | Paliris xr | Palitec xr | Vegadon sr</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Invega hafyera | Invega trinza</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Paliperidona aldesven | Paliperidona alter | Paliperidona teva | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Byannli | Invega | Invega Sustenna (Paliperidone Palmitate) | Trevicta</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Invega sustenna | Palipra | Trevicta</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Paliperidon krka | Palmeux | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Invega sustenna | Invega trinza</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Parnido | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Egoropal | Paliperidon | Parnido | Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Invega sustenna | Invega trinza</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Trevicta | Xeplion</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Berydone | Invega hafyera | Invega sustenna | Invega trinza | Pardone</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Byannli | Trevicta | Xeplion</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14662555">
<a name="14662555"></a>Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. <i>Arch Gen Psychiatry</i>. 2003;60(12):1228-1235. doi:10.1001/archpsyc.60.12.1228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/14662555/pubmed" id="14662555" target="_blank">14662555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20210726">
<a name="20210726"></a>Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. <i>Curr Drug Saf</i>. 2010;5(1):97-104. doi:10.2174/157488610789869265<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/20210726/pubmed" id="20210726" target="_blank">20210726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation. <i>Obstet Gynecol.</i> 2008;111(4):1001-1020. doi:10.1097/AOG.0b013e31816fd910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15003083">
<a name="15003083"></a>American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. <i>J Clin Psychiatry</i>. 2004;65(2):267-272. doi:10.4088/jcp.v65n0219<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/15003083/pubmed" id="15003083" target="_blank">15003083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14747245">
<a name="14747245"></a>American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. <i>Diabetes Care</i>. 2004;27(2):596-601. doi:10.2337/diacare.27.2.596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/14747245/pubmed" id="14747245" target="_blank">14747245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28861176">
<a name="28861176"></a>Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. <i>World J Diabetes</i>. 2017;8(8):390-396. doi:10.4239/wjd.v8.i8.390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/28861176/pubmed" id="28861176" target="_blank">28861176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bak.2014">
<a name="Bak.2014"></a>Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: A meta-analysis. PLoS ONE. 9(4):e94112. doi:10.1371/journal.pone.0094112</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9712220">
<a name="9712220"></a>Bark N. Deaths of psychiatric patients during heat waves. <i>Psychiatr Serv</i>. 1998;49(8):1088-1090. doi:10.1176/ps.49.8.1088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/9712220/pubmed" id="9712220" target="_blank">9712220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23295003">
<a name="23295003"></a>Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. <i>Psychosomatics</i>. 2013;54(1):1-13. doi:10.1016/j.psym.2012.11.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/23295003/pubmed" id="23295003" target="_blank">23295003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25578944">
<a name="25578944"></a>Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. <i>Drugs R D</i>. 2015;15(1):45-62. doi:10.1007/s40268-014-0078-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/25578944/pubmed" id="25578944" target="_blank">25578944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19825908">
<a name="19825908"></a>Berwaerts J, Cleton A, Rossenu S, et al. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. <i>J Psychopharmacol</i>. 2010;24(7):1011-1018. doi:10.1177/0269881109106914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/19825908/pubmed" id="19825908" target="_blank">19825908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19958039">
<a name="19958039"></a>Bhuvaneswar CG, Baldessarini RJ, Harsh VL, Alpert JE. Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. <i>CNS Drugs</i>. 2009;23(12):1003-1021. doi:10.2165/11530020-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/19958039/pubmed" id="19958039" target="_blank">19958039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33555955">
<a name="33555955"></a>Boels D, Mahé J, Olry A, Citterio-Quentin A, Moragny J, Jolliet P. Fatal and life-threatening ADRs associated with paliperidone palmitate: an observational study in the French pharmacovigilance database. <i>Clin Toxicol (Phila)</i>. 2021;59(9):786-793. doi:10.1080/15563650.2021.1878206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/33555955/pubmed" id="33555955" target="_blank">33555955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19113797">
<a name="19113797"></a>Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. <i>Pharmacotherapy</i>. 2009;29(1):64-73. doi:10.1592/phco.29.1.64<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/19113797/pubmed" id="19113797" target="_blank">19113797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17698676">
<a name="17698676"></a>Bouchama A, Dehbi M, Mohamed G, Matthies F, Shoukri M, Menne B. Prognostic factors in heat wave related deaths: a meta-analysis. <i>Arch Intern Med</i>. 2007;167(20):2170-2176. doi:10.1001/archinte.167.20.ira70009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/17698676/pubmed" id="17698676" target="_blank">17698676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33737254">
<a name="33737254"></a>Caballero ML, Krantz MS, Quirce S, Phillips EJ, Stone CA Jr. Hidden dangers: Recognizing excipients as potential causes of drug and vaccine hypersensitivity reactions. <i>J Allergy Clin Immunol Pract</i>. 2021;9(8):2968-2982. doi:10.1016/j.jaip.2021.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/33737254/pubmed" id="33737254" target="_blank">33737254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19364288">
<a name="19364288"></a>Calarge CA, Acion L, Kuperman S, Tansey M, Schlechte JA. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. <i>J Child Adolesc Psychopharmacol</i>. 2009;19(2):101-9. doi:10.1089/cap.2008.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/19364288/pubmed" id="19364288" target="_blank">19364288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20331935">
<a name="20331935"></a>Calarge CA, Zimmerman B, Xie D, Kuperman S, Schlechte JA. A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. <i>J Clin Psychiatry</i>. 2010;71(3):338-347. doi:10.4088/JCP.08m04595gre<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/20331935/pubmed" id="20331935" target="_blank">20331935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16529334">
<a name="16529334"></a>Canadian Psychiatric Association (CPA). Clinical practice guidelines. Treatment of schizophrenia. <i>Can J Psychiatry</i>. 2005;50(13)(suppl 1):7S-57S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/16529334/pubmed" id="16529334" target="_blank">16529334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28146614">
<a name="28146614"></a>Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: A meta-analysis. <i>J Clin Psychiatry</i>. 2017;78(3):e264-e278. doi:10.4088/JCP.16r10832<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/28146614/pubmed" id="28146614" target="_blank">28146614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12927004">
<a name="12927004"></a>Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. <i>J Clin Psychiatry</i>. 2003;64(8):898-906. doi:10.4088/jcp.v64n0807<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/12927004/pubmed" id="12927004" target="_blank">12927004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21172575">
<a name="21172575"></a>Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. <i>Neurol Clin</i>. 2011;29(1):127-48, viii. doi:10.1016/j.ncl.2010.10.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/21172575/pubmed" id="21172575" target="_blank">21172575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15151456">
<a name="15151456"></a>Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. <i>J Clin Psychiatry</i>. 2004;65(suppl 7):4-18; quiz 19-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/15151456/pubmed" id="15151456" target="_blank">15151456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23821039">
<a name="23821039"></a>Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. <i>CNS Drugs</i>. 2013;27(7):545-572. doi:10.1007/s40263-013-0079-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/23821039/pubmed" id="23821039" target="_blank">23821039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18533766">
<a name="18533766"></a>Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. <i>J Clin Psychiatry</i>. 2008;69(suppl 4):26-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/18533766/pubmed" id="18533766" target="_blank">18533766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19861668">
<a name="19861668"></a>Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents [published correction appearin in <i>JAMA</i>. 2009;302(21):2322]. <i>JAMA</i>. 2009;302(16):1765-1773. doi:10.1001/jama.2009.1549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/19861668/pubmed" id="19861668" target="_blank">19861668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955499">
<a name="29955499"></a>Crouse EL, Alastanos JN, Bozymski KM, Toscano RA. Dysphagia with second-generation antipsychotics: A case report and review of the literature. <i>Ment Health Clin</i>. 2018;7(2):56-64. doi:10.9740/mhc.2017.03.056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/29955499/pubmed" id="29955499" target="_blank">29955499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26574175">
<a name="26574175"></a>Danielsson B, Collin J, Jonasdottir Bergman G, Borg N, Salmi P, Fastbom J. Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study. <i>Br J Clin Pharmacol</i>. 2016;81(4):773-783. doi:10.1111/bcp.12829<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/26574175/pubmed" id="26574175" target="_blank">26574175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28883731">
<a name="28883731"></a>Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. <i>Neuropsychiatr Dis Treat</i>. 2017;13:2231-2241. doi:10.2147/NDT.S113099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/28883731/pubmed" id="28883731" target="_blank">28883731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22009159">
<a name="22009159"></a>De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. <i>Nat Rev Endocrinol</i>. 2011;8(2):114-126. doi:10.1038/nrendo.2011.156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/22009159/pubmed" id="22009159" target="_blank">22009159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22900950">
<a name="22900950"></a>De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. <i>CNS Drugs</i>. 2012;26(9):733-759. doi:10.2165/11634500-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/22900950/pubmed" id="22900950" target="_blank">22900950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22947594">
<a name="22947594"></a>Einarson TR, Hemels ME, Nuamah I, Gopal S, Coppola D, Hough D. An analysis of potentially prolactin-related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitate. <i>Ann Pharmacother</i>. 2012;46(10):1322-1330. doi:10.1345/aph.1R123<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/22947594/pubmed" id="22947594" target="_blank">22947594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23278567">
<a name="23278567"></a>Ely SF, Neitzel AR, Gill JR. Fatal diabetic ketoacidosis and antipsychotic medication. <i>J Forensic Sci</i>. 2013;58(2):398-403. doi:10.1111/1556-4029.12044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/23278567/pubmed" id="23278567" target="_blank">23278567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17414689">
<a name="17414689"></a>Evcimen H, Alici-Evcimen Y, Basil B, Mania I, Mathews M, Gorman JM. Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis. <i>J Psychiatr Pract</i>. 2007;13(2):117-119. doi:10.1097/01.pra.0000265770.17871.01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/17414689/pubmed" id="17414689" target="_blank">17414689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32678522">
<a name="32678522"></a>Ferreira LP, Ferreira TF, Godinho FF, et al. Priapism associated with atypical antipsychotic medications: A clinical report. <i>Prim Care Companion CNS Disord</i>. 2020;22(4):19l02543. doi:10.4088/PCC.19l02543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/32678522/pubmed" id="32678522" target="_blank">32678522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18098216">
<a name="18098216"></a>Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. <i>Hum Psychopharmacol</i>. 2008;23(suppl 1):27-41. doi:10.1002/hup.917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/18098216/pubmed" id="18098216" target="_blank">18098216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25581312">
<a name="25581312"></a>Fraser LA, Liu K, Naylor KL, et al. Falls and fractures with atypical antipsychotic medication use: a population-based cohort study. <i>JAMA Intern Med</i>. 2015;175(3):450-452. doi:10.1001/jamainternmed.2014.6930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/25581312/pubmed" id="25581312" target="_blank">25581312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gambhir.2014">
<a name="Gambhir.2014"></a>Gambhir S, Sandersfeld N, D'Mello D. A case of severe, refractory antipsychotic-induced orthostatic hypotension. <i>Med Student Res J</i>. 2014;4(fall):15-17.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24158020">
<a name="24158020"></a>Gareri P, De Fazio P, Manfredi VG, De Sarro G. Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. <i>J Clin Psychopharmacol</i>. 2014;34(1):109-123. doi:10.1097/JCP.0b013e3182a6096e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/24158020/pubmed" id="24158020" target="_blank">24158020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17548409">
<a name="17548409"></a>Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. <i>Ann Intern Med</i>. 2007;146(11):775-786. doi:10.7326/0003-4819-146-11-200706050-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/17548409/pubmed" id="17548409" target="_blank">17548409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23422378">
<a name="23422378"></a>Gopal S, Hough D, Karcher K, et al. Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials. <i>J Clin Psychopharmacol</i>. 2013;33(2):157-161. doi:10.1097/JCP.0b013e318283983f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/23422378/pubmed" id="23422378" target="_blank">23422378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28660406">
<a name="28660406"></a>Gopal S, Lane R, Nuamah I, et al. Evaluation of potentially prolactin-related adverse events and sexual maturation in adolescents with schizophrenia treated with paliperidone extended-release (ER) for 2 years: A post hoc analysis of an open-label multicenter study. <i>CNS Drugs</i>. 2017;31(9):797-808. doi:10.1007/s40263-017-0437-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/28660406/pubmed" id="28660406" target="_blank">28660406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24092977">
<a name="24092977"></a>Gopal S, Liu Y, Alphs L, Savitz A, Nuamah I, Hough D. Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies. <i>Neuropsychiatr Dis Treat</i>. 2013;9:1381-1392. doi:10.2147/NDT.S49944<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/24092977/pubmed" id="24092977" target="_blank">24092977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25358867">
<a name="25358867"></a>Gopal S, Xu H, Bossie C, et al. Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases. <i>Int J Clin Pract</i>. 2014 ;68(12):1514-1522. doi:10.1111/ijcp.12493<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/25358867/pubmed" id="25358867" target="_blank">25358867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21790209">
<a name="21790209"></a>Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. <i>CNS Drugs</i>. 2011;25(8):659-671. doi:10.2165/11591710-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/21790209/pubmed" id="21790209" target="_blank">21790209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18941580">
<a name="18941580"></a>Hansen A, Bi P, Nitschke M, Ryan P, Pisaniello D, Tucker G. The effect of heat waves on mental health in a temperate Australian city. <i>Environ Health Perspect</i>. 2008;116(10):1369-1375. doi:10.1289/ehp.11339<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/18941580/pubmed" id="18941580" target="_blank">18941580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20706126">
<a name="20706126"></a>Harrington CA, English C. Tolerability of paliperidone: a meta-analysis of randomized, controlled trials. <i>Int Clin Psychopharmacol</i>. 2010;25(6):334-341. doi:10.1097/YIC.0b013e32833db3d8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/20706126/pubmed" id="20706126" target="_blank">20706126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22834451">
<a name="22834451"></a>Hasan A, Falkai P, Wobrock T, et al; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World J Biol Psychiatry</i>. 2012;13(5):318-378. doi:10.3109/15622975.2012.696143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/22834451/pubmed" id="22834451" target="_blank">22834451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25168784">
<a name="25168784"></a>Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. <i>CNS Drugs</i>. 2014;28(10):887-920. doi:10.1007/s40263-014-0196-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/25168784/pubmed" id="25168784" target="_blank">25168784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910830">
<a name="28910830"></a>Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. <i>Pharmacopsychiatry</i>. 2018;51(1-02):9-62. doi:10.1055/s-0043-116492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/28910830/pubmed" id="28910830" target="_blank">28910830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirapara.2020">
<a name="Hirapara.2020"></a>Hirapara K, Munir A, Aggarwal R. Hypothermia associated with paliperidone depot injection in schizophrenia patient: A case report. <i>J Clin Psychopharmacol</i>. 2020;40(1):86-87.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16633146">
<a name="16633146"></a>Holzer L, Eap CB. Risperidone-induced symptomatic hyperprolactinaemia in adolescents. <i>J Clin Psychopharmacol</i>. 2006;26(2):167-171. doi:10.1097/01.jcp.0000203194.58087.9a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/16633146/pubmed" id="16633146" target="_blank">16633146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22410947">
<a name="22410947"></a>Hough DW, Gopal S, Coppola D, et al. Prolongation of cardiac ventricular repolarization under paliperidone: how and how much? <i>J Cardiovasc Pharmacol</i>. 2012;59(3):298-299. doi:10.1097/FJC.0b013e3182499e9a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/22410947/pubmed" id="22410947" target="_blank">22410947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20881844">
<a name="20881844"></a>Hough DW, Natarajan J, Vandebosch A, Rossenu S, Kramer M, Eerdekens M. Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. <i>Int Clin Psychopharmacol</i>. 2011;26(1):25-34. doi:10.1097/YIC.0b013e3283400d58<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/20881844/pubmed" id="20881844" target="_blank">20881844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10671383">
<a name="10671383"></a>Howard R, Rabins PV, Seeman MV, Jeste DV. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. <i>Am J Psychiatry</i>. 2000;157(2):172-178. doi:10.1176/appi.ajp.157.2.172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/10671383/pubmed" id="10671383" target="_blank">10671383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24556260">
<a name="24556260"></a>Hsieh MH, Chiu NY. Paliperidone-associated motor tics. <i>Gen Hosp Psychiatry</i>. 2014;36(3):360.e7-8. doi:10.1016/j.genhosppsych.2014.01.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/24556260/pubmed" id="24556260" target="_blank">24556260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29924506">
<a name="29924506"></a>Hsu JH, Mulsant BH, Lenze EJ, et al. Clinical predictors of extrapyramidal symptoms associated with aripiprazole augmentation for the treatment of late-life depression in a randomized controlled trial. <i>J Clin Psychiatry</i>. 2018;79(4):17m11764. doi:10.4088/JCP.17m11764<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/29924506/pubmed" id="29924506" target="_blank">29924506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29097257">
<a name="29097257"></a>Huang M, Yu L, Pan F, et al. A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2018;81:122-130. doi:10.1016/j.pnpbp.2017.10.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/29097257/pubmed" id="29097257" target="_blank">29097257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31303314">
<a name="31303314"></a>Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis [published correction appearing in <i>Lancet</i>. 2019;394(10202):918.]. <i>Lancet</i>. 2019;394(10202):939-951. doi:10.1016/S0140-6736(19)31135-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/31303314/pubmed" id="31303314" target="_blank">31303314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7730499">
<a name="7730499"></a>Huttunen M. The evolution of the serotonin-dopamine antagonist concept. <i>J Clin Psychopharmacol</i>. 1995;15(1)(suppl 1):4S-10S. doi:10.1097/00004714-199502001-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/7730499/pubmed" id="7730499" target="_blank">7730499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Invega.2022.03">
<a name="Invega.2022.03"></a>Invega (paliperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Invega.2020.12">
<a name="Invega.2020.12"></a>Invega (paliperidone) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Invega.2021.12">
<a name="Invega.2021.12"></a>Invega extended-release tablets (paliperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-InvegaHafyera.2021.08">
<a name="InvegaHafyera.2021.08"></a>Invega Hafyera (paliperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-InvegaSustenna.2021.08">
<a name="InvegaSustenna.2021.08"></a>Invega Sustenna (paliperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-InvegaSustenna.2020.12">
<a name="InvegaSustenna.2020.12"></a>Invega Sustenna (paliperidone) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-InvegaTrinza.2021.08">
<a name="InvegaTrinza.2021.08"></a>Invega Trinza (paliperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-InvegaTrinza.2020.12">
<a name="InvegaTrinza.2020.12"></a>Invega Trinza (paliperidone) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23151241">
<a name="23151241"></a>Iwamoto Y, Kawanishi C, Kishida I, et al. Dose-dependent effect of antipsychotic drugs on autonomic nervous system activity in schizophrenia. <i>BMC Psychiatry</i>. 2012;12:199. doi:10.1186/1471-244X-12-199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/23151241/pubmed" id="23151241" target="_blank">23151241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25140533">
<a name="25140533"></a>Jackson JW, Schneeweiss S, VanderWeele TJ, Blacker D. Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis. <i>PLoS One</i>. 2014;9(8):e105376. doi:10.1371/journal.pone.0105376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/25140533/pubmed" id="25140533" target="_blank">25140533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12046641">
<a name="12046641"></a>Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. <i>Ann Clin Psychiatry</i>. 2002;14(1):59-64. doi:10.1023/a:1015228112495<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/12046641/pubmed" id="12046641" target="_blank">12046641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24416588">
<a name="24416588"></a>Jones ME, Campbell G, Patel D, et al. Risk of mortality (including Sudden Cardiac Death) and Major Cardiovascular Events in Users of Olanzapine and Other Antipsychotics: A Study with the General Practice Research Database. <i>Cardiovasc Psychiatry Neurol</i>. 2013;2013:647476. doi:10.1155/2013/647476<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/24416588/pubmed" id="24416588" target="_blank">24416588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3819263">
<a name="3819263"></a>Jurivich DA, Hanlon J, Andolsek K. Neuroleptic-induced neutropenia in the elderly. <i>J Am Geriatr Soc</i>. 1987;35(3):248-50. doi:10.1111/j.1532-5415.1987.tb02317.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/3819263/pubmed" id="3819263" target="_blank">3819263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22193526">
<a name="22193526"></a>Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. <i>Am J Psychiatry</i>. 2012;169(1):71-79. doi:10.1176/appi.ajp.2011.11030347<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/22193526/pubmed" id="22193526" target="_blank">22193526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30811377">
<a name="30811377"></a>Kane JM, Correll CU, Delva N, Gopal S, Savitz A, Mathews M. Low incidence of neuroleptic malignant syndrome associated with paliperidone palmitate long-acting injectable: A database report and case study. <i>J Clin Psychopharmacol</i>. 2019;39(2):180-182. doi:10.1097/JCP.0000000000001019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/30811377/pubmed" id="30811377" target="_blank">30811377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26792046">
<a name="26792046"></a>Karslıoğlu EH, Özalp E, Çayköylü A. Paliperidone palmitate-induced urinary Incontinence: A case report. <i>Clin Psychopharmacol Neurosci</i>. 2016;14(1):96-100. doi:10.9758/cpn.2016.14.1.96<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/26792046/pubmed" id="26792046" target="_blank">26792046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28794632">
<a name="28794632"></a>Kattalai Kailasam V, Chima V, Nnamdi U, Sharma K, Shah K. Risperidone-induced reversible neutropenia. <i>Neuropsychiatr Dis Treat</i>. 2017;13:1975-1977. doi:10.2147/NDT.S141472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/28794632/pubmed" id="28794632" target="_blank">28794632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27721999">
<a name="27721999"></a>Kaur J, Kumar D, Alfishawy M, Lopez R, Sachmechi I. Paliperidone inducing concomitantly syndrome of inappropriate antidiuretic hormone, neuroleptic malignant syndrome, and rhabdomyolysis. <i>Case Rep Crit Care</i>. 2016;2016:2587963. doi:10.1155/2016/2587963<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/27721999/pubmed" id="27721999" target="_blank">27721999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32867516">
<a name="32867516"></a>Keepers GA, Fochtmann LJ, Anzia JM, et al; (Systematic Review). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. <i>Am J Psychiatry</i>. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/32867516/pubmed" id="32867516" target="_blank">32867516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20920543">
<a name="20920543"></a>Kim JN, Lee BC, Choi IG, Jon DI, Jung MH. Paliperidone-induced leukopenia and neutropenia: a case report. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2011;35(1):284-285. doi:10.1016/j.pnpbp.2010.09.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/20920543/pubmed" id="20920543" target="_blank">20920543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15863810">
<a name="15863810"></a>Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. <i>Am J Psychiatry</i>. 2005;162(5):1010-2. doi:10.1176/appi.ajp.162.5.1010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/15863810/pubmed" id="15863810" target="_blank">15863810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12766935">
<a name="12766935"></a>Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome--a case review. <i>Hum Psychopharmacol</i>. 2003;18(4):301-309. doi:10.1002/hup.483<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/12766935/pubmed" id="12766935" target="_blank">12766935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16174785">
<a name="16174785"></a>Kwok JS, Chan TY. Recurrent heat-related illnesses during antipsychotic treatment. <i>Ann Pharmacother</i>. 2005;39(11):1940-1942. doi:10.1345/aph.1G130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/16174785/pubmed" id="16174785" target="_blank">16174785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17650054">
<a name="17650054"></a>Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. <i>J Clin Psychiatry</i>. 2007;68(suppl 6):10-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/17650054/pubmed" id="17650054" target="_blank">17650054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24016844">
<a name="24016844"></a>Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbæk G. Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. <i>Am J Geriatr Psychiatry</i>. 2014;22(4):321-331. doi:10.1016/j.jagp.2013.06.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/24016844/pubmed" id="24016844" target="_blank">24016844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lauriello.1">
<a name="Lauriello.1"></a>Lauriello J, Campbell AR. Schizophrenia in adults: Pharmacotherapy with long-acting injectable antipsychotic medication. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed September 15, 2020. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23737244">
<a name="23737244"></a>La Torre A, Conca A, Duffy D, Giupponi G, Pompili M, Grözinger M. Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. <i>Pharmacopsychiatry</i>. 2013;46(6):201-208. doi:10.1055/s-0033-1347177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/23737244/pubmed" id="23737244" target="_blank">23737244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15000267">
<a name="15000267"></a>Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2 Suppl):1-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/15000267/pubmed" id="15000267" target="_blank">15000267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23810019">
<a name="23810019"></a>Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis [published correction appearing in <i>Lancet</i>. 2013;382(9896):940.]. <i>Lancet</i>. 2013;382(9896):951-962. doi:10.1016/S0140-6736(13)60733-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/23810019/pubmed" id="23810019" target="_blank">23810019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18849294">
<a name="18849294"></a>Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. S<i>chizophr Bull</i>. 2010;36(3):624-632. doi:10.1093/schbul/sbn120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/18849294/pubmed" id="18849294" target="_blank">18849294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26780600">
<a name="26780600"></a>Madan R, Langenfeld RJ, Ramaswamy S. Paliperidone palmitate-induced retrograde ejaculation. <i>Clin Schizophr Relat Psychoses</i>. 2018;12(2):86-88. doi:10.3371/csrp.MALA.123015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/26780600/pubmed" id="26780600" target="_blank">26780600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Martinez.2014">
<a name="Martinez.2014"></a>Martinez CP. Confused, cold, and lethargic. <i>Current Psychiatry</i>. 2014;13(2)71-76.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12190212">
<a name="12190212"></a>Martinez M, Devenport L, Saussy J, Martinez J. Drug-associated heat stroke. <i>South Med J</i>. 2002;95(8):799-802.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/12190212/pubmed" id="12190212" target="_blank">12190212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33549083">
<a name="33549083"></a>Martos N, Hall W, Marhefka A, Sedlak TW, Nucifora FC Jr. Paliperidone induced neutropenia in first episode psychosis: a case report. <i>BMC Psychiatry</i>. 2021;21(1):76. doi:10.1186/s12888-021-03073-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/33549083/pubmed" id="33549083" target="_blank">33549083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30498351">
<a name="30498351"></a>Mathews M, Nuamah I, Savitz AJ, et al. Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate. <i>Neuropsychiatr Dis Treat</i>. 2018;14:2807-2816. doi:10.2147/NDT.S175364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/30498351/pubmed" id="30498351" target="_blank">30498351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28140680">
<a name="28140680"></a>Mauri MC, Reggiori A, Paletta S, Di Pace C, Altamura AC. Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation. <i>Expert Opin Drug Saf</i>. 2017;16(3):365-379. doi:10.1080/14740338.2017.1288716<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/28140680/pubmed" id="28140680" target="_blank">28140680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25786075">
<a name="25786075"></a>Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. <i>JAMA Psychiatry</i>. 2015;72(5):438-445. doi:10.1001/jamapsychiatry.2014.3018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/25786075/pubmed" id="25786075" target="_blank">25786075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32068565">
<a name="32068565"></a>Mazhar F, Carnovale C, Haider N, Ahmed R, Taha M. Paliperidone-associated hyponatremia: Report of a fatal case with analysis of cases reported in the literature and to the US Food and Drug Administration Adverse Event Reporting System. <i>J Clin Psychopharmacol</i>. 2020;40(2):202-205. doi:10.1097/JCP.0000000000001180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/32068565/pubmed" id="32068565" target="_blank">32068565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17195735">
<a name="17195735"></a>McClellan J, Kowatch R, Findling RL; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(1):107-125. doi:10.1097/01.chi.0000242240.69678.c4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/17195735/pubmed" id="17195735" target="_blank">17195735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20823970">
<a name="20823970"></a>McKeown NJ, Bryan JH, Horowitz BZ. Catatonia associated with initiating paliperidone treatment. <i>West J Emerg Med</i>. 2010;11(2):186-188.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/20823970/pubmed" id="20823970" target="_blank">20823970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32670542">
<a name="32670542"></a>Moncrieff J, Gupta S, Horowitz MA. Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder. <i>Ther Adv Psychopharmacol</i>. 2020;10:2045125320937910. doi:10.1177/2045125320937910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/32670542/pubmed" id="32670542" target="_blank">32670542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31703010">
<a name="31703010"></a>Moodliar S, Naguy A, Elsori DH, AlKhadhari S. Paliperidone-associated priapism in an autistic child. <i>Am J Ther</i>. 2019;28(5):e610-e612. doi:10.1097/MJT.0000000000001107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/31703010/pubmed" id="31703010" target="_blank">31703010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8102845">
<a name="8102845"></a>Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. <i>Arch Gen Psychiatry</i>. 1993;50(9):723-733. doi:10.1001/archpsyc.1993.01820210057007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/8102845/pubmed" id="8102845" target="_blank">8102845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28558630">
<a name="28558630"></a>Morrison M, Schultz A, Sanchez DL, Catalano MC, Catalano G. Leukopenia associated with risperidone treatment. <i>Curr Drug Saf</i>. 2017 May 30. doi:10.2174/1574886312666170531072837<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/28558630/pubmed" id="28558630" target="_blank">28558630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20187598">
<a name="20187598"></a>Muench J, Hamer AM. Adverse effects of antipsychotic medications. <i>Am Fam Physician</i>. 2010;81(5):617-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/20187598/pubmed" id="20187598" target="_blank">20187598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21304113">
<a name="21304113"></a>Nayak RB, Bhogale GS, Patil NM, Chate SS, Pandurangi AA, Shetageri VN. Paliperidone-induced neuroleptic malignant syndrome. <i>J Neuropsychiatry Clin Neurosci</i>. 2011;23(1):E14-E15. doi:10.1176/jnp.23.1.jnpe14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/21304113/pubmed" id="21304113" target="_blank">21304113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33605644">
<a name="33605644"></a>Netcheva Z, Shin K. Late-onset neuroleptic malignant syndrome associated with paliperidone long-acting injection and lithium: A case report.<i> J Clin Psychopharmacol</i>. 2021;41(3):333-335. doi:10.1097/JCP.0000000000001370<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/33605644/pubmed" id="33605644" target="_blank">33605644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15998156">
<a name="15998156"></a>Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. <i>CNS Drugs</i>. 2005;(19 suppl 1):1-93. doi:10.2165/00023210-200519001-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/15998156/pubmed" id="15998156" target="_blank">15998156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20520598">
<a name="20520598"></a>Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. <i>Neuropsychopharmacology</i>. 2010;35(9):1997-2004. doi:10.1038/npp.2010.78<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/20520598/pubmed" id="20520598" target="_blank">20520598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22854034">
<a name="22854034"></a>Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. <i>Can J Psychiatry</i>. 2012;57(8):512-518. doi:10.1177/070674371205700810<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/22854034/pubmed" id="22854034" target="_blank">22854034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22533871">
<a name="22533871"></a>Nunes LV, Moreira HC, Razzouk D, Nunes SO, Mari Jde J. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. <i>J Sex Marital Ther</i>. 2012;38(3):281-301. doi:10.1080/0092623X.2011.606883<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/22533871/pubmed" id="22533871" target="_blank">22533871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27478670">
<a name="27478670"></a>Omi T, Riku K, Fukumoto M, et al. Paliperidone induced hypoglycemia by increasing insulin secretion. <i>Case Rep Psychiatry</i>. 2016;2016:1805414. doi:10.1155/2016/1805414<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/27478670/pubmed" id="27478670" target="_blank">27478670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14565800">
<a name="14565800"></a>O'Neill JL, Remington TL. Drug-induced esophageal injuries and dysphagia. <i>Ann Pharmacother</i>. 2003;37(11):1675-1684. doi:10.1345/aph.1D056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/14565800/pubmed" id="14565800" target="_blank">14565800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29569043">
<a name="29569043"></a>Onken M, Mick I, Schaefer C. Paliperidone and pregnancy-an evaluation of the German Embryotox database. <i>Arch Womens Ment Health</i>. 2018 ;21(6):657-662. doi:10.1007/s00737-018-0828-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/29569043/pubmed" id="29569043" target="_blank">29569043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25599999">
<a name="25599999"></a>Özdemir AK, Pak ŞC, Canan F, Geçici Ö, Kuloğlu M, Gücer MK. Paliperidone palmitate use in pregnancy in a woman with schizophrenia. <i>Arch Womens Ment Health</i>. 2015;18(5):739-740. doi:10.1007/s00737-014-0496-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/25599999/pubmed" id="25599999" target="_blank">25599999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29028688">
<a name="29028688"></a>Papadopoulou A, Gkikas K, Efstathiou V, et al. Angioedema associated with long-acting injectable paliperidone palmitate: A case report. <i>J Clin Psychopharmacol</i>. 2017;37(6):730-732. doi:10.1097/JCP.0000000000000788<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/29028688/pubmed" id="29028688" target="_blank">29028688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31325958">
<a name="31325958"></a>Patterson-Lomba O, Ayyagari R, Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis.<i> BMC Neurol</i>. 2019;19(1):174. doi:10.1186/s12883-019-1385-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/31325958/pubmed" id="31325958" target="_blank">31325958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9735957">
<a name="9735957"></a>Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. <i>Psychiatr Serv</i>. 1998;49(9):1163-1172. doi:10.1176/ps.49.9.1163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/9735957/pubmed" id="9735957" target="_blank">9735957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22180550">
<a name="22180550"></a>Perry R, Wolberg J, DiCrescento S. Anaphylactoid reaction to paliperidone palmitate extended-release injectable suspension in a patient tolerant of oral risperidone. <i>Am J Health Syst Pharm</i>. 2012;69(1):40-43. doi:10.2146/ajhp110230<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/22180550/pubmed" id="22180550" target="_blank">22180550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Post.1">
<a name="Post.1"></a>Post RM. Bipolar disorder in adults: choosing maintenance treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed September 30, 2021. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28252452">
<a name="28252452"></a>Potkin SG, Loze JY, Forray C, et al. Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY. <i>Int Clin Psychopharmacol</i>. 2017;32(3):147-154. doi:10.1097/YIC.0000000000000168<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/28252452/pubmed" id="28252452" target="_blank">28252452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30925499">
<a name="30925499"></a>Pu ZP, Li GR, Zou ZP, Tao F, Hu SH. A randomized, 8-week study of the effects of extended-release paliperidone and olanzapine on heart rate variability in patients with schizophrenia. <i>J Clin Psychopharmacol</i>. 2019;39(3):243-248. doi:10.1097/JCP.0000000000001023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/30925499/pubmed" id="30925499" target="_blank">30925499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22984110">
<a name="22984110"></a>Raj V, Druitt T, Purushothaman S, Dunsdon J. Risperidone/paliperidone induced neutropenia and lymphopenia. <i>Aust N Z J Psychiatry</i>. 2013;47(3):291-2912. doi:10.1177/0004867412460594<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/22984110/pubmed" id="22984110" target="_blank">22984110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15949658">
<a name="15949658"></a>Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? <i>Schizophr Res</i>. 2005;76(2-3):267-272. doi:10.1016/j.schres.2005.01.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/15949658/pubmed" id="15949658" target="_blank">15949658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27133416">
<a name="27133416"></a>Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association (APA) practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. <i>Am J Psychiatry</i>. 2016;173(5):543-546. Accessed May 26, 2016. doi:10.1176/appi.ajp.2015.173501  http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2015.173501.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/27133416/pubmed" id="27133416" target="_blank">27133416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24241935">
<a name="24241935"></a>Rodríguez-Martínez A, Quilo CG. Paliperidone extended-release: safety and tolerability from a metabolic profile perspective. <i>Clin Drug Investig</i>. 2013;33(12):867-876. doi:10.1007/s40261-013-0100-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/24241935/pubmed" id="24241935" target="_blank">24241935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33686614">
<a name="33686614"></a>Rognoni C, Bertolani A, Jommi C. Second-generation antipsychotic drugs for patients with schizophrenia: Systematic literature review and meta-analysis of metabolic and cardiovascular side effects. <i>Clin Drug Investig</i>. 2021;41(4):303-319. doi:10.1007/s40261-021-01000-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/33686614/pubmed" id="33686614" target="_blank">33686614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26218604">
<a name="26218604"></a>Rojo LE, Gaspar PA, Silva H, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. <i>Pharmacol Res</i>. 2015;101:74-85. doi:10.1016/j.phrs.2015.07.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/26218604/pubmed" id="26218604" target="_blank">26218604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25914108">
<a name="25914108"></a>Samalin L, Lauron S, Llorca PM. Interest of clozapine and paliperidone palmitate plasma concentrations to monitor treatment in schizophrenic patients on chronic hemodialysis. <i>Schizophr Res.</i> 2015;166(1-3):351-352. doi:10.1016/j.schres.2015.04.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/25914108/pubmed" id="25914108" target="_blank">25914108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26218669">
<a name="26218669"></a>Savitz A, Lane R, Nuamah I, Singh J, Hough D, Gopal S. Long-term safety of paliperidone extended release in adolescents with schizophrenia: An open-label, flexible dose study. <i>J Child Adolesc Psychopharmacol</i>. 2015;25(7):548-557. doi:10.1089/cap.2014.0130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/26218669/pubmed" id="26218669" target="_blank">26218669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29776316">
<a name="29776316"></a>Schoretsanitis G, Spina E, Hiemke C, de Leon J. A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. <i>Expert Rev Clin Pharmacol</i>. 2018;11(6):625-639. doi:10.1080/17512433.2018.1478727<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/29776316/pubmed" id="29776316" target="_blank">29776316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22722501">
<a name="22722501"></a>Schreiner A, Niehaus D, Shuriquie NA, Aadamsoo K, Korcsog P, Salinas R, Theodoropoulou P, Fernández LG, Uçok A, Tessier C, Bergmans P, Hoeben D. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial [published correction appearing in <i>J Clin Psychopharmacol</i>. 2012;32(6):803]. <i>J Clin Psychopharmacol</i>. 2012;32(4):449-457. doi:10.1097/JCP.0b013e31825cccad<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/22722501/pubmed" id="22722501" target="_blank">22722501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19213967">
<a name="19213967"></a>Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. <i>Psychosomatics</i>. 2009;50(1):8-15. doi:10.1176/appi.psy.50.1.8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/19213967/pubmed" id="19213967" target="_blank">19213967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32648200">
<a name="32648200"></a>Seo DE, Kim S, Park BJ. Signals of adverse drug reactions of paliperidone compared to other atypical antipsychotics using the Korean Adverse Event Reporting System database. <i>Clin Drug Investig</i>. 2020;40(9):873-881. doi:10.1007/s40261-020-00945-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/32648200/pubmed" id="32648200" target="_blank">32648200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32715655">
<a name="32715655"></a>Shymko G, Grace T, Jolly N, et al. Weight gain and metabolic screening in young people with early psychosis on long acting injectable antipsychotic medication (aripiprazole vs paliperidone). <i>Early Interv Psychiatry</i>. 2021;15(4):787-793. doi:10.1111/eip.13013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/32715655/pubmed" id="32715655" target="_blank">32715655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24559194">
<a name="24559194"></a>Sliwa JK, Fu DJ, Bossie CA, Turkoz I, Alphs L. Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate. <i>BMC Psychiatry</i>. 2014;14:52. doi:10.1186/1471-244X-14-52<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/24559194/pubmed" id="24559194" target="_blank">24559194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17390261">
<a name="17390261"></a>Soares-Weiser K, Fernandez HH. Tardive dyskinesia. <i>Semin Neurol</i>. 2007;27(2):159-169. doi:10.1055/s-2007-971169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/17390261/pubmed" id="17390261" target="_blank">17390261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28721057">
<a name="28721057"></a>Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. <i>Ther Clin Risk Manag</i>. 2017;13:757-777. doi:10.2147/TCRM.S117321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/28721057/pubmed" id="28721057" target="_blank">28721057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29439776">
<a name="29439776"></a>Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. <i>J Neurol Sci</i>. 2018;389:21-27. doi:10.1016/j.jns.2018.02.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/29439776/pubmed" id="29439776" target="_blank">29439776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23343447">
<a name="23343447"></a>Spanarello S, La Ferla T. The pharmacokinetics of long-acting antipsychotic medications. <i>Curr Clin Pharmacol</i>. 2014;9(3):310-317. doi:10.2174/15748847113089990051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/23343447/pubmed" id="23343447" target="_blank">23343447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33195656">
<a name="33195656"></a>Srifuengfung M, Sukakul T, Liangcheep C, Viravan N. Paliperidone palmitate-induced facial angioedema: A case report. <i>World J Clin Cases</i>. 2020;8(20):4876-4882. doi:10.12998/wjcc.v8.i20.4876<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/33195656/pubmed" id="33195656" target="_blank">33195656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Steinman.1">
<a name="Steinman.1"></a>Steinman M, Reeve E. Deprescribing. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed September 30, 2021. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18628446">
<a name="18628446"></a>Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. doi:10.1345/aph.1L066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/18628446/pubmed" id="18628446" target="_blank">18628446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22549762">
<a name="22549762"></a>Stigler KA, Mullett JE, Erickson CA, et al. Paliperidone for irritability in adolescents and young adults with autistic disorder. <i>Psychopharmacology (Berl)</i>. 2012;223(2):237-245. doi:10.1007/s00213-012-2711-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/22549762/pubmed" id="22549762" target="_blank">22549762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33903594">
<a name="33903594"></a>Stogios N, Gdanski A, Gerretsen P, et al. Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health. <i>NPJ Schizophr</i>. 2021;7(1):22. doi:10.1038/s41537-021-00151-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/33903594/pubmed" id="33903594" target="_blank">33903594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955530">
<a name="29955530"></a>Stoner SC. Management of serious cardiac adverse effects of antipsychotic medications. <i>Ment Health Clin</i>. 2018;7(6):246-254. doi:10.9740/mhc.2017.11.246<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/29955530/pubmed" id="29955530" target="_blank">29955530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30192094">
<a name="30192094"></a>Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. <i>World Psychiatry</i>. 2018;17(3):341-356. doi:10.1002/wps.20567<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/30192094/pubmed" id="30192094" target="_blank">30192094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stroup.2022">
<a name="Stroup.2022"></a>Stroup TS, Marder S. Schizophrenia in adults: maintenance therapy and side effect management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26928057">
<a name="26928057"></a>Struye A, Depuydt C, Abdel Sater E, Dubois V. Toxic epidermal necrolysis related to paliperidone palmitate: First case report. <i>J Clin Psychopharmacol</i>. 2016;36(3):279-282. doi:10.1097/JCP.0000000000000482<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/26928057/pubmed" id="26928057" target="_blank">26928057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30271152">
<a name="30271152"></a>Suda A, Hattori S, Kishida I, et al. Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients. <i>Neuropsychiatr Dis Treat</i>. 2018;14:2361-2366. doi:10.2147/NDT.S173617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/30271152/pubmed" id="30271152" target="_blank">30271152</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24047427">
<a name="24047427"></a>Suzuki H, Gen K, Inoue Y, et al. The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. <i>Int J Psychiatry Clin Pract</i>. 2014;18(1):58-62. doi:10.3109/13651501.2013.845218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/24047427/pubmed" id="24047427" target="_blank">24047427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22144033">
<a name="22144033"></a>Suzuki Y, Fukui N, Watanabe J, et al. QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone. <i>Hum Psychopharmacol</i>. 2012;27(1):39-42. doi:10.1002/hup.1258<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/22144033/pubmed" id="22144033" target="_blank">22144033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28044008">
<a name="28044008"></a>Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G. Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. <i>Schizophr Bull</i>. 2017;43(4):862-871. doi:10.1093/schbul/sbw171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/28044008/pubmed" id="28044008" target="_blank">28044008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22231327">
<a name="22231327"></a>Teng PR, Lane HY. Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone. <i>J Neuropsychiatry Clin Neurosci</i>. 2011;23(4):E16-E17. doi:10.1176/jnp.23.4.jnpe16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/22231327/pubmed" id="22231327" target="_blank">22231327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: A scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients [published correction appearing in <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(6):e57]. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24803473">
<a name="24803473"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients [published correction appearing in <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(6):981]. <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(3):381-390. doi:10.1161/CIRCOUTCOMES.113.000651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/24803473/pubmed" id="24803473" target="_blank">24803473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22626633">
<a name="22626633"></a>Trollor JN, Chen X, Chitty K, Sachdev PS. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. <i>Br J Psychiatry</i>. 2012;201(1):52-56. doi:10.1192/bjp.bp.111.105189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/22626633/pubmed" id="22626633" target="_blank">22626633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10473482">
<a name="10473482"></a>van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. <i>BMJ</i>. 1999;319(7210):623-626. doi:10.1136/bmj.319.7210.623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/10473482/pubmed" id="10473482" target="_blank">10473482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17401555">
<a name="17401555"></a>van Marum RJ, Wegewijs MA, Loonen AJ, Beers E. Hypothermia following antipsychotic drug use. <i>Eur J Clin Pharmacol</i>. 2007;63(6):627-631. doi:10.1007/s00228-007-0294-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/17401555/pubmed" id="17401555" target="_blank">17401555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18348593">
<a name="18348593"></a>van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. <i>J Clin Psychiatry</i>. 2008;69(3):472-479. doi:10.4088/jcp.v69n0320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/18348593/pubmed" id="18348593" target="_blank">18348593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23812796">
<a name="23812796"></a>Vieweg WV, Hasnain M, Hancox JC, et al. Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports. <i>Psychopharmacology (Berl)</i>. 2013;228(4):515-524. doi:10.1007/s00213-013-3192-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/23812796/pubmed" id="23812796" target="_blank">23812796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21394035">
<a name="21394035"></a>Vigneault P, Kaddar N, Bourgault S, et al. Prolongation of cardiac ventricular repolarization under paliperidone: how and how much? <i>J Cardiovasc Pharmacol</i>. 2011;57(6):690-695. doi:10.1097/FJC.0b013e318217d941<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/21394035/pubmed" id="21394035" target="_blank">21394035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30636434">
<a name="30636434"></a>Wakuda T, Suzuki A, Hasegawa M, Ichikawa D, Yamasue H. Acute agranulocytosis when switching from risperidone to paliperidone. <i>Aust N Z J Psychiatry</i>. 2019;53(6):586-587. doi:10.1177/0004867418821441<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/30636434/pubmed" id="30636434" target="_blank">30636434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23858394">
<a name="23858394"></a>Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. <i>Tremor Other Hyperkinet Mov (N Y)</i>. 2013;3:tre-03-161-4138-1. doi:10.7916/D88P5Z71<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/23858394/pubmed" id="23858394" target="_blank">23858394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24740252">
<a name="24740252"></a>Wearne D. A case of priapism associated with paliperidone. <i>Aust N Z J Psychiatry</i>. 2014;48(10):962. doi:10.1177/0004867414532551<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/24740252/pubmed" id="24740252" target="_blank">24740252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22154659">
<a name="22154659"></a>Wei HT, Lai YW, Chen MH, Chen YS. Oral-paliperidone-induced tardive dyskinesia: a case report. <i>Gen Hosp Psychiatry</i>. 2012;34(5):578.e5-6. doi:10.1016/j.genhosppsych.2011.11.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/22154659/pubmed" id="22154659" target="_blank">22154659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22114630">
<a name="22114630"></a>Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. <i>Dtsch Arztebl Int</i>. 2011;108(41):687-693. doi:10.3238/arztebl.2011.0687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/22114630/pubmed" id="22114630" target="_blank">22114630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31534873">
<a name="31534873"></a>Williams GD. Cross-reaction of angioedema with clozapine, olanzapine, and quetiapine: A case report. <i>Ment Health Clin</i>. 2019;9(5):315-317. doi:10.9740/mhc.2019.09.315<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/31534873/pubmed" id="31534873" target="_blank">31534873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25497507">
<a name="25497507"></a>Wu CY, Mitchell SR, Seyfried LS. Quetiapine-induced hyperglycemic crisis and severe hyperlipidemia: a case report and review of the literature. <i>Psychosomatics</i>. 2014;55(6):686-691. doi:10.1016/j.psym.2014.07.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/25497507/pubmed" id="25497507" target="_blank">25497507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33520321">
<a name="33520321"></a>Yeung HM, Schmitz S, Kvantaliani N, Martin C. Development of neuroleptic malignant syndrome in a patient with Lewy Body Dementia after intramuscular administration of paliperidone. <i>Case Rep Neurol Med</i>. 2021;2021:8879333. doi:10.1155/2021/8879333<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/33520321/pubmed" id="33520321" target="_blank">33520321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26125544">
<a name="26125544"></a>Yucel A, Yucel N, Ozcan H, Saritemur M. Dose-dependent paliperidone associated with angioedema. <i>J Clin Psychopharmacol</i>. 2015;35(5):615-616. doi:10.1097/JCP.0000000000000368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/26125544/pubmed" id="26125544" target="_blank">26125544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27414740">
<a name="27414740"></a>Zamora Rodríguez FJ, Benítez Vega C, Sánchez-Waisen Hernández MR, Guisado Macías JA, Vaz Leal FJ. Use of paliperidone palmitate throughout a schizoaffective disorder patient's gestation period. <i>Pharmacopsychiatry</i>. 2017;50(1):38-40. doi:10.1055/s-0042-110492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/27414740/pubmed" id="27414740" target="_blank">27414740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24446539">
<a name="24446539"></a>Zhang Y, Dai G. Efﬁcacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China. <i>Hum Psychopharmacol</i>. 2012;27(6):605-614. doi:10.1002/hup.2270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/24446539/pubmed" id="24446539" target="_blank">24446539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34481200">
<a name="34481200"></a>Zhu Y, Zhang C, Siafis S, et al. Prolactin levels influenced by antipsychotic drugs in schizophrenia: A systematic review and network meta-analysis. <i>Schizophr Res</i>. 2021;237:20-25. doi:10.1016/j.schres.2021.08.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/34481200/pubmed" id="34481200" target="_blank">34481200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28936184">
<a name="28936184"></a>Zonnenberg C, Bueno-de-Mesquita JM, Ramlal D, Blom JD. Hypothermia due to antipsychotic medication: A systematic review. <i>Front Psychiatry</i>. 2017;8:165. doi:10.3389/fpsyt.2017.00165<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paliperidone-pediatric-drug-information/abstract-text/28936184/pubmed" id="28936184" target="_blank">28936184</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 87122 Version 386.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
